

Exhibit B

UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF VIRGINIA
Alexandria Division

NICHOLAS HARRISON and
OUTSERVE-SLDN, INC.

Plaintiffs,

v.

Case No. 1:18-cv-641 (LMB/IDD)

JAMES N. MATTIS, in his official capacity
as Secretary of Defense; MARK ESPER, in
his official capacity as the Secretary of the
Army; and the UNITED STATES
DEPARTMENT OF DEFENSE,

Defendants.

**EXPERT DECLARATION OF CARLOS DEL RIO, M.D., IN SUPPORT OF
PLAINTIFFS' MOTION FOR PRELIMINARY INJUNCTION**

I. INTRODUCTION

1. My name is Carlos del Rio. I have been retained by counsel for Plaintiffs as an expert in connection with this litigation.

2. I am offering this declaration to provide my expert opinions regarding HIV—its etiology, the mechanism by which it operates to undermine a person’s immune system, the routes and relative risks of transmission, the care and treatment of people living with HIV, the effect of treatment with antiretrovirals on the immunological and overall health of people living with HIV, and the effect of treatment on the risks of transmission.

3. The opinions I express are my own and do not reflect the official policy of any organization with which I am affiliated. I am not receiving any compensation for my work.

4. I am knowledgeable about the matters set forth below based upon my own knowledge and experience, as well as my review of various materials cited herein.

II. PROFESSIONAL BACKGROUND & QUALIFICATIONS

5. I am the Hubert Professor and Chair of the Department of Global Health and Professor of Epidemiology at the Rollins School of Public Health and Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine. I am also Principal Investigator and co-Director of the Emory Center for AIDS Research (CFAR).

6. I am a native of Mexico where I attended medical school at Universidad La Salle, graduating in 1983. I did my Internal Medicine and Infectious Diseases residencies at Emory University. In 1989, I returned to Mexico where I was Executive Director of the National AIDS Council of Mexico (CONASIDA, the Federal agency of the Mexican Government responsible for AIDS Policy throughout Mexico) from 1992 through 1996. In November 1996, I returned to Emory where I have been involved in patient care, teaching and research. I was Chief of the

Emory Medical Service at Grady Memorial Hospital from 2001 to 2009 and I am now the interim Executive Associate Dean for Emory at Grady.

7. My research focuses on early diagnosis, access to care, engagement in care, compliance with antiretrovirals and prevention of HIV. I am the co-Primary Investigator of the NIH-funded Emory-CDC HIV Clinical Trials Unit, Clinical Site Leader for the Adult AIDS Clinical Trials Group (ACTG) and the site Primary Investigator for the HIV Prevention Trials Network (HPTN) of the NIAID/NIH. My international work includes collaborations in the following countries: Georgia, Ethiopia, Kenya, Thailand, Vietnam and Mexico. I have also worked on emerging infections, such as pandemic influenza, and was a member of the WHO Influenza A(H1N1) Clinical Advisory Group and of the CDC Influenza A(H1N1) Task Force during the 2009 pandemic.

8. I am a Member of the Board of Directors of the International Antiviral Society-USA (IAS-USA) and was the Chair of the HIVMA of the Infectious Diseases Society of America (IDSA). I was also a member of the Advisory Committee on HIV, Hepatitis and STD Prevention and Treatment of the Centers for Disease Control and Prevention and Health Resources and Services Administration as well as of the Department of Health and Human Services (DHHS) Antiretroviral Treatment Guidelines Panel. I serve as Chief Section Editor for HIV/AIDS for NEJM Journal Watch Infectious Diseases, Associate Editor for Clinical Infectious Diseases and I am a member of the editorial board of the Journal of AIDS and Global Public Health.

9. I have co-authored 30 book chapters and over 300 scientific papers. Among other honors, I received the James H. Nakano Citation in 2001 and was recognized by the Centers for Disease Control and Prevention for an outstanding scientific paper published in 2000; awarded

the Emory University Marion V. Creekmore Achievement Award for Internationalization; selected by the “Atlanta Magazine” as one of the 55 most influential foreign-born Atlantans in 2007. In 2013, I was elected to the Institute of Medicine of the National Academies.

10. My curriculum vitae is attached, which describes my education, work experience, and publications. *See* Attach. 1 (del Rio CV).

III. BACKGROUND ON THE HUMAN IMMUNODEFICIENCY VIRUS

A. An Introduction to HIV

11. Since Acquired Immune Deficiency Syndrome (AIDS) was first identified as a cause of death in the United States in the early 1980s, there has been incredible progress in the treatment of this disease. Once considered invariably fatal within a matter of years, HIV is now considered a chronic, manageable condition. Those diagnosed in a timely manner and provided with appropriate care and treatment with antiretroviral medications experience no noticeable effects on their physical health and enjoy a life expectancy that is nearly the same as those who do not have HIV.

12. HIV, which is an acronym for human immunodeficiency virus, attacks the body’s immune system. Specifically, HIV attacks the body’s CD4 cells, also referred to as T-cells. When HIV takes over a CD4 cell, it forces the cell to produce multiple copies of the virus, which in turn take over other CD4 cells.

13. CD4 cells help the immune systems fight off other types of infections. As HIV reduces the number CD4 cells in the body, it becomes increasingly harder for a person to fend off infections or disease.

14. After the acute stage of infection, a person enters a period of clinical latency that can last years. After time, however, if the person does not receive appropriate treatment, the

amount of virus in their blood (i.e., their “viral load”) will rise and their CD4 count will start to drop. Eventually, an untreated individual’s CD4 count will drop below 200 and/or the person will develop an infection the body would be able to fight off under normal circumstances (i.e., an “opportunistic infection”), at which point that person would have an AIDS diagnosis.

B. The Treatment of HIV

15. At almost any point in the progression of HIV, however, consistent treatment with antiretroviral therapy will halt and reverse the downward slope in immune function and restore the person to good health.

16. In 1996, effective antiretroviral therapy (ART) became widely available. In the mid-1990’s, medical researchers discovered that a combination of three antiretroviral medications (from at least two different subclasses) would not only prevent HIV from reproducing, but would also prevent the virus from mutating and becoming resistant to the medications, as had been the problem with mono and dual therapy approaches. .

17. With adherence to ART, the person’s viral load drops and their CD4 count rebounds. Within several months, the person’s HIV will become “virally suppressed,” defined as less than 200 copies of the virus per milliliter of blood,¹ and shortly after that, they would have an “undetectable”² viral load, which is generally defined as less than 50 copies per milliliter of blood. .

¹ See U.S. Centers for Disease Control and Prevention, *Evidence of HIV Treatment and Viral Suppression in Preventing the Sexual Transmission of HIV* (Dec. 2017), available at <https://www.cdc.gov/hiv/pdf/risk/art/cdc-hiv-art-viral-suppression.pdf>; U.S. Centers for Disease Control and Prevention, *HIV Treatment as Prevention*, available at www.cdc.gov/hiv/risk/art (“[V]iral suppression [is] defined as having less than 200 copies of HIV per milliliter of blood.”).

² At one time, the testing technologies were not sensitive enough to reliably detect the virus below approximately 50 copies per milliliter. Newer testing technologies are able to detect HIV

18. Every person living with HIV who adheres to their antiretroviral medications will eventually achieve and maintain an undetectable viral load. There is an effective treatment regimen for virtually every person living with HIV, and difficulties in reaching an undetectable viral load are related to a lack of consistent access to the health care and/or other social determinants of health, such as instable housing or food insecurity, that make medication adherence more difficult.

19. Development of resistance to a particular ART regimen does not occur unless the patient is not adherent to their prescribed medications. One of the important features of the ART regimens used today is that if the virus is suppressed the development of mutations that lead to resistance becomes impossible. With three or more medications combatting the virus in different ways at the same time, the virus is not able to mutate around any of those medications. For patients who develop resistance due to non-adherence, switching to a different regimen to which their virus has not developed resistance and to which they are subsequently adherent will return that patient to viral suppression.

20. As drugs have less and less side effects, adherence to ART has grown easier and easier over the past 20 years. Today, most people living with HIV are on a single tablet regimen (“STR”)—in which all three or four medications are combined into one pill—that is taken once a day. STRs have no dietary restrictions, and side effects are minimal and generally very well tolerated.

below this level, but the term “undetectable” is still used to describe a viral load at or below this level.

21. A person who is diagnosed with HIV in a timely manner and adheres to their prescribed ART has very nearly the same life expectancy as a person who is not living with HIV.³

C. The Transmission of HIV

22. HIV can only be transmitted via certain body fluids—blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk.⁴ For transmission to occur, these fluids from a person who has HIV must either come in contact with a mucous membrane or damaged tissue or be directly injected into the bloodstream (with a needle or syringe). Mucous membranes are found inside the rectum, vagina, penis, and mouth. HIV is not spread through saliva, sweat, tears, urine, or feces.

23. Most commonly, HIV is transmitted by engaging in sexual activities or sharing needles or syringes. Outside of the contexts of sexual activity, sharing of injection drug equipment, blood transfusion, needle sticks, or perinatal exposure (including breastfeeding), transmission of HIV is rare. For all other activities—including biting, spitting, and throwing of body fluids—the CDC characterizes the risk as “negligible” and further states that “HIV transmission through these exposure routes is technically possible but unlikely and not well documented.”⁵

³ See U.S. Centers for Disease Control and Prevention, *About HIV/AIDS*, available at <https://www.cdc.gov/hiv/basics/whatishiv.html>.

⁴ See U.S. Centers for Disease Control and Prevention, *HIV Transmission*, available at <https://www.cdc.gov/hiv/basics/transmission.html>.

⁵ See U.S. Centers for Disease Control and Prevention, *HIV Risk Behaviors: Estimated Per-Act Probability of Acquiring HIV from an Infected Source, by Exposure Act*, available at www.cdc.gov/hiv/risk/estimates/riskbehaviors.html.

24. Contrary to popular belief, HIV is not an easily transmitted virus. In the absence of treatment and condom use, the CDC estimates that the per-act risk of transmission for the riskiest sexual activity—receptive anal intercourse—is approximately 1.38% (138 out of 10,000 exposures).⁶ The per-act risk of transmission for other sexual activities is between zero and .08%.

25. Furthermore, people living with HIV who are virally suppressed or have an undetectable viral load are incapable of transmitting HIV. Advances in understanding of the preventive effects of ART have led the CDC to declare that “...people who take ART daily as prescribed and achieve and maintain an undetectable viral load have effectively no risk of sexually transmitting the virus to an HIV negative partner. See CDC, “Dear Colleague: Information from CDC’s Division of HIV/AIDS Prevention,” Sept. 27, 2017, *available at* <https://www.cdc.gov/hiv/library/dcl/dcl/092717.html> (last viewed June 26, 2018).⁷

26. As further stated in the CDC letter, “Across three different studies, including thousands of couples and many thousands of acts of sex without a condom or pre-exposure prophylaxis (PrEP), no HIV transmissions to an HIV-negative partner were observed when the HIV-positive person was virally suppressed”⁸ (i.e., a viral load of less than 200 copies/ml).

⁶ See U.S. Centers for Disease Control and Prevention, *HIV Risk Behaviors: Estimated Per-Act Probability of Acquiring HIV from an Infected Source, by Exposure Act*, available at www.cdc.gov/hiv/risk/estimates/riskbehaviors.html.

⁷ See U.S. Centers for Disease Control and Prevention, *Treatment as Prevention*, available at www.cdc.gov/hiv/risk/art (“People living with HIV who take HIV medicine as prescribed and get and keep an undetectable viral load have effectively no risk of transmitting HIV to their HIV-negative sexual partners.”).

⁸ The referenced scientific studies: The HIV Prevention Treatment Network Study No. 052 as published in the *New England Journal of Medicine* 08/11/11, *available at* <https://www.nejm.org/doi/full/10.1056/NEJMoa1105243?query=recirc> curated Related article; PARTNER Study, published in the *Journal of the American Medical Association (JAMA)* July


27. Based on these studies regarding the effect of a suppressed or undetectable viral load on sexual transmission risk and the extremely low—and possibly only theoretical—risk of transmission via blood splash and other non-injection activities, I am reasonably certain that it is not possible for a person with a suppressed or undetectable viral load to transmit HIV through such exposures.

IV. CONCLUSION

HIV is now a relatively easy to manage, chronic condition that, when properly treated, presents no cognizable risk to the health or safety of others through occupational exposures, including exposures that could potentially occur during military service.

I declare under penalty of perjury that the foregoing is true and correct.

Executed this 18 day of July, 2018



Carlos del Rio, M.D.

12, 2016, available at <https://ncbi.nlm.nih.gov/pubmed/27404185>; and Opposites Attract study reported at the Conference on Retroviruses and Opportunistic Infections (CROI) in 2015, available at <https://www.croiconference.org/sites/default/files/posters-2015/1019LB.pdf> and the International AIDS Conference in 2017.

Attachment

**EMORY UNIVERSITY
CURRICULUM VITAE**

Name: CARLOS DEL RIO, MD

Office Address: 1518 Clifton Road NE Phone: (404) 727-7112
Claudia N. Rollins Building, 7011 Fax: (404) 727-1278
Atlanta GA 30322

E-mail Address: cdelrio@emory.edu

Birth Date and Place: August 28, 1959. Mexico City, Mexico

Citizenship: United States of America and Mexico

Websites:

<http://medicine.emory.edu/infectious-diseases/faculty-directory/del-rio-carlos.html> &
<https://sph.emory.edu/faculty/profile/#!/cdelrio>

ResearcherID:

<http://www.researcherid.com/ProfileView.action?returnCode=ROUTER.Success&Init=Yes&SrcApp=CR&queryString=KG0UuZjN5WmP6yAsUHlIBIEGQkwtKoQLBlp0gCLTBbs%253D&SID=7Co6dCuimpqh4njckXt>

Current Titles and Affiliations:

a. Academic appointments:

April 1, 2009 – present: Hubert Professor & Chair, Hubert Dept. of Global Health,
Rollins School of Public Health of Emory University

Sept. 1, 2003 – present: Professor of Medicine (Tenured), Emory University School of
Medicine

b. Clinical Appointments:

March 1997 – July 2011: Active Medical Staff, Grady Health System

Oct 1999 – present: Medical Staff member, The Emory Clinic

July 2011 – present: Active-Courtesy staff member, Grady Health System

June 2013 – present: Infectious Diseases Clinical Chief of Service at Emory University
Hospital

c. Other administrative appointments:

Jan 16, 2017 – present: Interim Executive Associate Dean for Emory at Grady

Oct 1, 2005 – present: Co-Director, Emory Center for AIDS Research.

Jan. 1, 2007 – present: Clinical Research Site (CRS) Leader at the Ponce de Leon Center
for the Emory AIDS Clinical Trials Group (ACTG).

Previous Academic and Professional Appointments:

1990 – 1996: Associate Professor of Medicine, Universidad La Salle, Mexico City, Mexico.

1989 – 1996: Chief of Infectious Diseases and Chairman of the Infection Control
Committee, Hospital Angeles del Pedregal, Mexico City, Mexico.

1993 – 1999: National Investigator, National Research Council (Sistema Nacional de Investigadores), Mexico.
1996 – 1997: Assistant Professor of Medicine (transient appointment), Emory University School of Medicine (EUSM).
1997 – 2001: Associate Director for Clinical Services at the Ponce de Leon Center of the Grady Health System and Director of the Special Immunology Service at Grady Memorial Hospital
September 1, 1997 – August 31, 2003: Associate Professor of Medicine (Infectious Diseases), Emory University School of Medicine
December 18, 1997 – August 31, 2005: Adjunct Associate Professor of International Health, Rollins School of Public Health, Emory University
September 1, 2005 – March 31, 2009: Adjunct Professor of Global Health, Rollins School of Public Health, Emory University.

Previous Administrative Appointments:

1992 – 1994: Executive Director of the National AIDS Council (CONASIDA), Mexico.
1994 – 1996: General Coordinator of the National AIDS Council (CONASIDA), Mexico.
1995 – 1997: Member of the Program Coordinating Board, Joint United Nations Program on HIV/AIDS (UNAIDS)
July 1999 – July 2000: Associate Director of the Internal Medicine Residency Program
January 1998 – July 2001: Director, Clinical Core of the Emory CFAR
July 1, 2000 – March 31, 2001: Program Director, Emory Internal Medicine Residency Program
April 1, 2001 - January 31, 2006: Co-Director, J. Willis Hurst Internal Medicine Program.
April 1, 2001 - March 31, 2009: Chief of Medical Service, Grady Memorial Hospital
February 1, 2006 – February 29, 2008: Director for Resident Scholarly Activities, J. Willis Hurst Internal Medicine Residency Program.
July 1, 2001 – September 30, 2005: Associate Director for Clinical Sciences and International Research, Emory Center for AIDS Research
July 1, 2004 – June 1, 2006: Executive Director, Hope Clinic of the Emory Vaccine Center.
February 1, 2006 – March 31, 2009: Vice Chair for Grady Affairs, Dept. of Medicine, EUSM
March 1, 2008 – May 31, 2010: Program Director, J. Willis Hurst Internal Medicine Residency Program of Emory University.
Sept. 1998 – June 2015: Director and Principal Investigator, AIDS International Training and Research Program (AITRP) of Emory University.

Licensures/Boards:

Georgia Medical License: 027282
1981: ECFMG (Educational Commission for Foreign Medical Graduates)
1982: VQE (Visa Qualifying Examination)
1984: FLEX (Federation Licensing Examination)

Specialty Boards:

- 1986, American Board of Internal Medicine (#108785)
- 1988, American Board of Internal Medicine (Infectious Diseases)

Education:

- 1977-83: Medical School, Universidad La Salle, Mexico City, Mexico
- 1981-82: Pregraduate internship (senior year of medical school), six months at the University of Oregon, Portland, Oregon and six months at Emory University, Atlanta, Georgia
- 1982-83: Social service, Department of Critical Care Medicine, Instituto Nacional de la Nutrición Salvador Zubirán, Mexico City, Mexico

Postgraduate Training:

- 1983-86: Internal Medicine Residency, Emory University School of Medicine, Atlanta, Georgia (five months in JAR year at Johns Hopkins Hospital, Baltimore, MD)
- 1986-88: Infectious Disease Fellowship, Emory University School of Medicine, Atlanta, Georgia
- 1988-89: Chief Resident in Medicine at Crawford Long Hospital of Emory University, Atlanta, Georgia

Executive Training:

- Jan 2007: Program for Chiefs of Clinical Services. Department of Health Policy and Management, Harvard School of Public Health.
- Jan 2008: Woodruff Health Sciences Center Quality Academy.

Committee Memberships:

- a. National and International:
 - Member of the Scientific Advisory Committee of the Latin-American AIDS Initiative (SIDALAC) (1996 – 2000)
 - Member of the Monitoring of the AIDS Pandemic (MAP) Network (1996 – 2000)
 - Chair, Committee on the Status of Minority Microbiologists, Public and Scientific Affairs Board, American Society for Microbiology (June 1997 - June 2003)
 - CDC, Member of the Task Force to develop the “*HIV Prevention Strategic Plan Through 2005*” (February 2000).
 - Member of the CDC Advisory Committee on HIV and STD Prevention (September 2000 – November 2003)
 - Member of the UNAIDS Performance Monitoring and Evaluation Plan Working Group (1997)
 - NIH Office of AIDS Research, Member of the Planning Group on International AIDS Research Priorities (April, 2001 and February 2002)
 - NIH, Chairman of Special Emphasis Panel for NIH NOT AI-01-018 “*Comprehensive International Program of Research on AIDS*” (August, 2001)
 - NIH, Member of Special Emphasis Panel for NH-00-0048 “*Early detection of HIV: Implications for Prevention Research*” (June 2000)
 - NIH, Member of Special Emphasis Panel for NH-00-004 “*Long-term Maintenance of HIV/STD Behavior Change*” (June 2000)
 - Elizabeth Glaser Pediatric AIDS Foundation, Member of Review Panel for “Call for Action Projects” (January 1996 to present)

- Member, Institute of Medicine’s Committee on the Ryan White Care Act: Data for Resource Allocation, Planning and Evaluation. (January 2002 – October 2003).
- NIH, Member of the Outcomes Committee of the Adult AIDS Clinical Trials Group (July 2001 – December 2006)
- Member, International AIDS Society – USA Core Faculty (April 2002 to present)
- NIH, Chairman of Special Emphasis Panel ZAI1-GPJ-A-S2 “*Comprehensive International Program of Research on AIDS - CIPRA*” (May, 2003)
- CDC, Member Special Emphasis Panel 2003-N-008922 “*A US Clinical Trial Site to Conduct Evaluation of Topical Microbicides in Heterosexual Women and Men*” (August, 2003)
- Member, Education Committee, Infectious Diseases Society of America (2003 – 2005)
- NIH, Member of Special Emphasis Panel ICP-2 “*International Bioethics Reviews*” (March 2004)
- NIH, Member of Special Emphasis Panel ZAI1 GP J-M (M1) “*NIAID Enhancement Awards for Underrepresented Minority Scientists*” (June 28 – 30, 2004)
- CDC, Member on Special Emphasis Panel PA 04156, “*Simplified Procedures for Routine HIV Screening in Acute Care Settings*” (August 17, 2004)
- NIH – Charter Member of the AIDS Clinical Studies and Epidemiology Study Section (formerly AARR-6), November 2004 – July 2009.
- Member of the Board of Directors, International AIDS Society – USA (January 2005 – present)
- NIH, Member of Special Emphasis Panel ZAI1 LD-A-J1 “*Unsolicited Research Project Grant Application*” (January 2006)
- NIH, Member of Special Emphasis Panel ZAI1 SV-A (S1) “*TB/HIV Immune Cell Expression*” (August 2006)
- NIH, Chair of Special Emphasis Panel ZAI1QV-1 “*Review of Clinical Trials and Implementation Grants*” (September 2006)
- NIH, Member of Special Emphasis Panel ZRG1 IC2-B (51) “*Phase II Comprehensive ICOHRTA-AIDS/TB (U2R) Review*” (November 2006)
- Representative of HIVMA on the Education Committee of IDSA (2006 – 2010)
- External Reviewer of the draft report by the Committee on the “*President’s Emergency Plan for AIDS [PEPFAR] Implementation Evaluation*”. (November 2006)
- Member, Institute of Medicine’s Committee on Methodological Challenges in HIV Prevention Trials (January 2007 – February 2008).
- Member, DHHS Panel for Antiretroviral Guidelines for Adults and Adolescents (February 2007 – February 2010 and February 2010 – February 2014)
- NIH, Member of Special Emphasis Panel ZAI1 ESB-A (M1) “*HIV Prevention in Men Review*” (April 2007)
- NIH, Member of Special Emphasis Panel ZRG1 BDA-A (52) “*FICRS Resource and Support Center Review*” (April 2007)
- CDC, Member of Special Emphasis Panel ZPS1 FXR (03) “*Minority HIV/AIDS Research Initiative to Build Capacity in Black and Hispanic Communities and Among Black and Hispanic Researchers to Conduct HIV/AIDS Epidemiologic and Prevention Research – MARF*” (May 2007)

- NIH, Member of Special Emphasis Panel ZAI1 SR-M (1) “*NIAID Clinical Trials Planning Grants*” (June 2007)
- Member of the Board of Directors of the HIVMA - HIV Medicine Association of IDSA - (October 2007 – Oct 2017)
 - Chair of the Board (Oct 2015 – Oct 2016)
- Member of the Board of Advisors of HealthSTAT (July 2007 – present)
- NIH, Member of Special Emphasis Panel ZRG1 ICP2-B (51) “*Global Infectious Diseases Training Program*” (February 2008)
- NIH, Member of Special Emphasis Panel ZRG1 ICP2-B (50) “*International Research in Infectious Diseases*” (February 2008)
- NIH, Member of Special Emphasis Panel ZDA1 NXR-B 13 1, “*International Collaborations for HIV and Drug Abuse*” (April 2, 2008)
- Member of the OpMAN (Optimization of Co-Infection and Co-Morbidity Committee) of the AIDS Clinical Trials Group (May 2008 – May 2010)
- Member of the Advisory Committee on HIV and STD Prevention and Treatment of the Centers for Disease Control and Prevention and Health Resources and Services Administration (July 1, 2008 – June 30, 2012 and July 1, 2012 – December 30, 2016)
- NIH, Member of Special Emphasis Panel ZDA1 NXR-B 08 1, “*Pre-Applications for the Avant-Garde Program*” (April 19, 2009)
- NIH, Member of Special Emphasis Panel ZRG1 AARR-C 22 “*AIDS Fellowship Review*” (July 28-29, 2009)
- Member, Institute of Medicine Committee on HIV Social Security Disability Criteria (Dec 2009 – June 2010)
- Member, WHO Influenza A(H1N1) Clinical Advisory Group (2009)
- Member, CDC Influenza A(H1N1) Task Force (2009)
- NIH, Member of Special Emphasis Panel ZCA1 RTRB-8 M2 R “*A Developing Research Capacity in Africa for the Studies of HIV-Associated Malignancies*” (March 15, 2010)
- NIH, Member of Special Emphasis Panel ZDA1 NXR-B 08 1, “*Pre-Applications for the Avant-Garde Program*” (April 23, 2010)
- Member of the ACTG Executive Committee (June 1, 2010 – May 31, 2013)
- Member of the Board of Directors of the Infectious Diseases Society of America (October 2010 – September 2013)
- Member, Institute of Medicine Committee to Review Data Systems for Monitoring HIV Care (February 2011 – September 2012)
- NIH, Member of Special Emphasis Panel ZRG1 IDM-R (50) R, “*International Research in Infectious Diseases including AIDS (IRIDA)*”. (February 11, 2011)
- NIH, Chair, Special Emphasis Panel ZRG1 F12B-U (20) L, “*Fellowships: Psychopathology, Disabilities, Stress and Aging*.” (February 24, 2011)
- NIH, Member of Special Emphasis Panel ZDA1 NXR-B 15, “*Pre-Applications for the 2011 Avant-Garde Program for HIV/AIDS Research*” (March 28, 2011)
- NIH/NIAID – Charter Member, Acquired Immunodeficiency Syndrome Research Review Committee (AIDS RRC), (July 1, 2011 – June 30, 2015).
- NIH, Member of Special Emphasis Panel ZRG1 AARR-H (55) “*Career Development in International Settings*”. (June 29, 2011)

- NIH/FIC – Member, US-India Joint Working Group on Prevention of Sexually Transmitted Diseases and HIV/AIDS (Oct 31, 2011)
- NIH, Member of Special Emphasis Panel ZDA1 NXR-B, “Pre-Applications for the Avant-Garde Program” (Jan 11, 2012)
- NIH, Chair of Special Emphasis Panel ZRG1 AARR-H, “HIV International Research Training” (Oct 31 – Nov 1, 2012)
- Member of the Board of Director, ACTHIV (April 2013 – present)
- Co-Chair, International Antiviral Society-USA Panel on Development of Recommendations for Biomedical Prevention of HIV Infection (2013)
- NIH, member of Special Emphasis Panel ZAI1 BP-A (S4), “Clinical Trials Implementation UO1 Grants” (Aug 26, 2013)
- NIH, member of Special Emphasis Panel ZRG1 AARR-F (52), “Methodologies and Formative Work for Combination HIV Prevention Approaches” (Dec 16, 2013)
- Member, Office of HIV/AIDS Network Coordination (HANC) Behavioral Sciences Consultative Group (Jan 1, 2015 – Dec 31, 2018)
- NIH/NIAID – Chair, Acquired Immunodeficiency Syndrome Research Review Committee (AIDS RRC), (July 1, 2014 – June 30, 2017)
- Member, UNAIDS Scientific and Technical Advisory Committee (Dec 2014 – present)
- Member, Fulton County Task Force on HIV/AIDS (Dec 2014 – Sept 2017)
- Chair, PEPFAR Scientific Advisory Board (March 1, 2015 – present)
- Vice-Chair, ACTG Underrepresented Populations Committee (Dec 1, 2016 – Nov 30, 2018)

b. Regional and State:

- Member of the Scientific Advisory Committee of the AIDS consortium of Atlanta (1996 – 2004)
- Member of the Board, AID Atlanta (1998 – 2004)
- Member of the Board of Trustees, The Paideia School (1998 – 2004)
- Member of the Parent Council of Emory University (2007 – 2010)
- Member of the Board of Directors, Atlanta Symphony Orchestra (2011 – present)

c. Institutional

- LCME Graduate Medical Education/Continuing Education Committee (1998)
- Dean of School of Nursing Search Committee (1999)
- GME Advisory Committee (July 1999 - present)
- Representative of the School of Medicine on the International Affairs Council (November 2000 to 2009)
- Member of the School of Medicine Faculty Committee on Appointments and Promotions (June 2001 – September 2004)
- Member of the Faculty Council of Emory University (2000- 2004)
- Member, Advisory Board of the Center for the Study of Health, Culture and Society (December 2000 – May 2009)
- Internal Medicine House Staff Evaluation Committee (March 1998 - present)
- Orthopedic Chair Search Committee (2001)
- Medical Executive Committee, Grady Health System (April 2001 – March 2009)

- Chair, Education and Training Subcommittee, Woodruff Health Sciences Center Bioterrorism Taskforce (April 2002 – December 2003)
- Representative of the School of Medicine on the Coordinating Committee for University Internationalization (September 2002 – April 2009)
- Chair, Medical Records Committee, Grady Health System (May 2002 – December 2005)
- Member, EMCF Practice Committee (June 2002 – March 2009)
- Member, Emory GCRC Advisory Committee (June 2002 – June 2007)
- Radiology Chair Search Committee (2003-2004)
- Member, Emory University Strategic Planning Committee (Subcommittees on Global Health and Internationalization).
- Co-Chair, Curriculum Planning Steering Committee of Emory University School of Medicine (September 2004 – December 2005)
- GCRC Director Search Committee (2005)
- Member, Faculty Development Committee for the Department of Medicine (2005 – 2009)
- Chair, Department of Medicine Promotions and Tenure Subcommittee (2005 – 2007)
- Member, Honorary Degrees Committee of Emory University (2006 – 2009)
- Member, Global Health Institute Advisory Committee, Emory University (2006 – present)
- Member, Institute for Developing Nations Academic Board, Emory University (2006 – present)
- Co-Chair Task Force on Faculty and Staff Development, Emory University School of Medicine (December 2006 – August 2007)
- Member, Search Advisory Committee for the Senior Vice President for Health Affairs of the Woodruff Health Sciences Center of Emory University (January – July 2007)
- Member, LCME Faculty Subcommittee (2007)
- Member, Presidential Advisory Committee (PAC) of Emory University (September 2007 – August 2009)
- Member, Surgery Chair Search Advisory Committee (2007-08)
- Member, Director of Critical Care for Emory Healthcare Search Advisory Committee (2008-09)
- Member, Research Advisory Committee of the School of Medicine (March 1, 2009 – August 31, 2010)
- Member, Woodruff Health Sciences Center Research Advisory Council (April 2009 – present)
- Chair of the Research Training and Education subcommittee for the WHSC Research Strategic Plan (August 2009 – May 2010)
- Co-Chair, Culture Transformation Group, Woodruff Health Sciences Center (May 2009 – May 2011).
- Member, Task Force on Protest, Dissent and Community (May 2011 – May 2015)
- Member, Emory University Faculty Advisory Committee for Finance and Administration (Oct 2011 – May 2015)
- Member, Family and Preventive Medicine Chair Search Committee (2012)

- Member, Graduate Medical Education Strategic Planning Committee (2013)
- Member, Director of Yerkes National Primate Research Center Search Committee (2013)
- Member, LCME Taskforce (2015)
- Co-Chair, Emory University's Provost Search Advisory Committee (Oct 2016 – 2017)

Consultantships:

- Centers for Disease Control and Prevention, Consultant for the drafting of the "*HIV Prevention Strategic Plan Through 2005*". September 2000.
- Centers for Disease Control and Prevention, External consultant for the "*Control of Neisseria gonorrhoeae infection in the United States*". Oct 10 – 11, 2001.
- Centers for Disease Control and Prevention, Consultant on "*Bioterrorism Education for Clinicians*", August 2002.
- Abbott Laboratories. HOPE Partnership (December 2001 – December 2002)
- Centers for Disease Control and Prevention, Consultant on implementing HIV Testing in Acute Care Settings. March 2004.
- NIH/Harvard Medical School Division of AIDS, Participant in the scientific workshop addressing "*When to Switch HIV Antiviral Therapy in Resource-Limited Settings*". Boston, MA. November 12, 2004.
- Centers for Disease Control and Prevention, Participant in Satellite Broadcast/Web Cast "*Incorporating HIV Prevention into the Medical Care of Persons Living with HIV*". November 13, 2004.
- Centers for Disease Control and Prevention, Consultant in drafting the "*HIV Screening Recommendations for Adults, Adolescents, and Pregnant Women in Health Care Settings*". November 1 – 2, 2005. Published as "*Revised Recommendations for HIV testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings*". *MMWR* 2006; 55(RR-14)
- Interagency Task Force on Antimicrobial Resistance, Consultant in drafting "*A Public Health Action Plan to Combat Antimicrobial Resistance*". December 12-13, 2007.
- Centers for Disease Control and Prevention, consultant for the "*External Peer Review of DHAP Surveillance, Research, and HIV Prevention Programs*". April 13 – 15, 2009
- Centers for Disease Control and Prevention, consultant for the "*Consultation on Revised Guidelines for HIV Counseling, Testing, and Referral in non-clinical settings*". June 1 – 2, 2009.
- Centers for Disease Control and Prevention, consultant during a meeting entitled: "*Developing a Rapid Impact Assessment Framework for Pandemic Influenza Response*". August 26, 2010
- Centers for Disease Control and Prevention, consultant for the "*Consultation on Monitoring and Use of Laboratory Data Reported to HIV Surveillance*". Jan 12 – 13, 2011
- Centers for Disease Control and Prevention, consultant for the "*Consultation on MSM Pre-Exposure Prophylaxis (PrEP) Implementation Guidelines*". May 3 – 4, 2011.

- Centers for Disease Control and Prevention, consultant for the “*HIV surveillance Case Definition*”. Feb 7 – 8, 2012.
- Centers for Disease Control and Prevention, consultant for the “*STD Treatment Guidelines 2013*”. April 30 – May 2, 2013.

Editorship and Editorial Boards:

- Chief Editor, HIV/AIDS *Journal Watch Infectious Diseases (2014 – present)*
- Associate Editor for HIV, *Clinical Infectious Diseases (2016 – present)*
- Senior Clinical Editor, *AIDS Research and Human Retroviruses (2007 – 2017)*
- Editorial board, *AIDS Clinical Care (2000 – 2014)*
- Editorial Board, *Journal of AIDS*
- Editorial Board, *Global Public Health*
- Editorial Board, *Women, Children and HIV*
- Editorial board, *Archives of Medical Research*

Manuscript reviewer

- AIDS
- AIDS Research and Human Retroviruses
- AIDS and Behavior
- American Journal of Medicine
- American Journal of Public Health
- American Journal of Preventive Medicine
- American Journal of the Medical Sciences
- Annals of Internal Medicine
- Annals of Emergency Medicine
- Archives of Internal Medicine
- Archives of Medical Research
- Clinical Infectious Diseases
- Emerging Infectious Diseases
- Gaceta Médica de México
- JAMA
- Journal of AIDS
- Journal of General Internal Medicine
- Journal of Infectious Diseases
- Lancet
- New England Journal of Medicine
- PLoS One
- Salud Pública de México
- Sexually Transmitted Infections
- Social Sciences and Medicine
- Vaccine

Honors and Awards:

- 1982 Valedictorian, medical school class of 1982, Universidad La Salle, Mexico
- 1983 Awarded "Los mejores estudiantes de México" (Best students in Mexico)
- 1987 Elected member of A.O.A.
- 1988 Trainee Travel Award, American Federation for Clinical Research
- 1990 Fellow of the American College of Physicians
- 1989, 91, 96 Physician Recognition Award, American Medical Association
- 1992-99 "Investigador Nacional Nivel I" (National Researcher) by the "Sistema Nacional de Investigadores" in Mexico
- 1993 Award "Hermano Miguel" given by the Universidad La Salle in Mexico in recognition of academic achievement
- 1996 Glaxo-Wellcome Foundation Award for Clinical Research. Mexico City, Mexico.
- 1996 Fellow of the Infectious Diseases Society of America
- 2001 James H. Nakano Citation (for an outstanding scientific paper published in 2000)
- 2002 Finalist, Atlanta Business Chronicle "Health-Care Heroes" Award in the

- Physician category
- 2006 Outstanding Achievement Award in the Field of HIV/AIDS awarded by the First Lady of Georgia for "*Personal Contribution in Developing a modern HIV/AIDS Control Program in Georgia*"
- 2007 Marion V. Creekmore Award for Internationalization, Emory University
- 2006, 2007, 2009, 2010, 2011, 2012, 2013 and 2017 "Best Conference Award", as voted by the residents for the most outstanding conference in the Emory Internal Medicine Residency Program.
- 2007 Selected by "*Atlanta Magazine*" as one of the 55 most influential foreign-born Atlantans (October 2007 issue)
- 2009 Elected member of the American Clinical and Climatological Association
- 2011 Elected member of the American Epidemiological Society
- 2011 Silver Pear Research Mentoring Award, Department of Medicine, Emory Univ.
- 2013 Fellows Award for Distinguished Educator in Infectious Diseases, University of Pittsburgh Division of Infectious Diseases
- 2013 Elected to the National Academy of Medicine (formerly the Institute of Medicine)
- 2014 Winner of the Thomas Jefferson Award at Emory University
- 2015 Winner of the Department of Medicine R. Wayne Alexander Research Achievement Award
- 2015 Department of Medicine Research Day, 3rd place winner in the "Clinical, Quality and Health Services Research Poster" category.
- 2016 Elected to Delta Omega (Honorary Society in Public Health) by the member students of the Phi Chapter at the Rollins School of Public Health
- 2016 Recipient of the "Ohtli Award" from the Mexican Government for "*distinguished work that benefits the interests of the Mexican community or communities of Mexican origin living in the US*".
- 2017 John P. McGovern Award Lectureship delivered at the 47th Annual Meeting of the American Osler Society. Atlanta, GA April 10th, 2017.
- 2017 Distinguished Medical Alumni Achievement Award – Emory University School of Medicine
- 2017 Inducted to the Emory MilliPub Club (The MilliPub Club honors and recognizes Emory faculty who have published one or more papers that have garnered more than 1,000 citations).
- 2017 Winner of the Emory University School of Medicine Mentoring Award

Society Memberships:

- American College of Physicians
- Member of the American Society for Microbiology
- Asociación Mexicana de Medicina Interna
- Infectious Diseases Society of America
- Asociación Mexicana de Infectología y Microbiología Clínica
- American Federation for Medical Research
- International AIDS Society

Organization of National or International Conferences:a. Administrative positions:

- Organizing committee of the 8th International Pathogenic *Neisseria* Conference, October 1992, Cuernavaca, Mexico
- Coordinator of the IV National AIDS Conference, October 1993, Mexico City, Mexico
- Organizing committee of the IV International Conference on Travel Medicine, April 1995, Acapulco, Mexico
- Coordinator of the V National AIDS Conference, November 1995, Mexico City, Mexico
- Scientific Committee, 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 2001
- Track Co-chair, 2001 National HIV Prevention Conference, Atlanta, GA, August 2001
- Scientific Program Committee Member, 3rd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Kampala, Uganda. September 2001.
- International Scientific Committee, XIV International Conference on AIDS, Barcelona, Spain, July 2002
- Scientific Program Committee, 8th World STI/AIDS Congress, Punta del Este, Uruguay, December 2-5, 2003.
- Joint Program Committee Track Co-chair, XVI International Conference on AIDS, Mexico City, Mexico, August 2008.
- Track Co-chair, 2009 National HIV Prevention Conference, Atlanta, GA, August 2009
- Planning Committee Member, 36th Remington Winter Course in Infectious Diseases. Vail, CO. February 21 - 26, 2010
- Co-Chair, AIDS Vaccine 2010. Atlanta, GA. September 28 – October 1, 2010
- Regional Chair, HIVDART 2010. Los Cabos, Mex. December 7 – 10, 2010
- Planning Committee Member, 37th Remington Winter Course in Infectious Diseases. Snowmass, CO. February 6 – 11, 2011
- Member, Clinical Science Track Committee, XIX International Conference on AIDS, Washington, DC. July 22 – 27, 2012
- Member, Scientific Advisory Committee, 2nd International Treatment as Prevention (TasP) Workshop. Vancouver, BC. April 22 – 25, 2012
- Member, Scientific Advisory Committee, 3rd International Treatment as Prevention (TasP) Workshop. Vancouver, BC. April 22 – 25, 2013
- Co-Chair of Planning Committee, The American Conference for the Treatment of HIV (ACTHIV), Denver, Co. May 8 – 10, 2014
- Scientific Advisory Committee, HIVDART 2014. Key Biscayne, Fla. December 9 – 12, 2014
- Member of the Scientific Program Committee, HIV Drug Therapy in the Americas 2015. Mexico City, Mx. April 16 – 18, 2015.
- Co-Chair of Planning Committee, The American Conference for the Treatment of HIV (ACTHIV), Dallas, Tx. Apr 29 – May 3, 2015
- Member of the Core Committee, HIV & Hepatitis in the Americas 2016. Mexico City, Mx. April 28 – 30, 2016.
- Member of the Core Committee, HIV & Hepatitis in the Americas 2017. Rio de Janeiro, Brazil. April 6 – 8, 2017.

Research focus:

My research efforts focus on access to care, linkage to care and barriers to care among HIV-infected hard to reach populations in the United States and abroad. I also do research on treatment and prevention of HIV/AIDS as well as adherence and the impact of therapy on behavior. I also work on TB and other co-infections like HCV and STI's, in particular gonorrhea. Finally, my research has expanded to include the emerging opioid epidemic and looking for ways to improve opioid prescribing and management of pain in clinical settings.

Grant Support:a. Active support:

- NIH (2P30 AI 50409). Emory CFAR. (PI: C. del Rio) 08/01/17 – 7/31/22.
- NIH/NIAID (AI069418). Emory-Duke-Orlando-CDC Clinical Trials Unit. (co-PIs: J. Lennox; C. del Rio & M. Mulligan) 12/10/13 – 11/30/20
- NIH/NIDA (1R01DA037768). Improving Physician Opioid Prescribing for Chronic Pain in HIV-infected Persons (co-PIs: J. Samet & C. del Rio), 09/15/2014 – 08/31/2018.
- NIH/NIDA (1R01DA032098-03). Project Retain: Providing Integrated Care for HIV-infected crack cocaine users (co-PIs: L. Metsch & C. del Rio), 07/15/2011 – 04/30/2017 (no cost extension).
- CDC (1H25-PS004311). The Emory Atlanta Gonococcal Isolate Surveillance Project - GISP (PI: C. del Rio), 01/01/14 - 12/31/18.
- NIH/NIDA (5U10DA013720). Florida Node of the Drug Abuse Clinical Trials Network (PI: J. Szapocznik & L. Metsch; Emory site PI: C del Rio) 00/30/2000 – 08/31/2020
- CDC (5T01GH001185). Emory Center for Public Health Training in Complex Humanitarian Emergencies (PI: C. del Rio) 9/1/2015 – 08/31/2018
- NIH (D43 TW007124). Emory-Georgia Tuberculosis Research Training Program (PI: H. Blumberg; Co-PI: C. del Rio), 09/30/04 - 06/30/19.
- NIH (D43 TW009127) Emory-Ethiopia Tuberculosis Research Training Program (PI: H. Blumberg; Co-PI: C. del Rio), 07/1/13 - 01/31/18.

Lectureship, Seminar Invitations, and Visiting Professorship: (last ten years)

- * *“Global and regional priorities in Infectious Diseases”*. Opening plenary talk at the XLII Congress of the National Infectious Diseases Society of Mexico. Puebla, Mx. May 24, 2017
- * *“Top 10 in HIV”*. Closing Plenary Speaker at the 11th Annual ACTHIV meeting. Dallas, TX April 20-22, 2017.
- * *“Improving patient outcomes by focusing on the HIV Care Continuum”*. Keynote speaker at the Symposium: Emerging Strategies for HIV and Viral Hepatitis Co-Infection Symposium. Atlanta, GA. Dec 1st, 2016.
- * *“What reviewers look for in your RPG application: perspectives from reviewers”*. Invited talk at the NIAID Research Career (“K”) Development: Fostering Science Leaders Workshop. NIH/NIAID Bethesda, MD. November 29, 2016.
- * *“Health Equity: Improving outcomes in Hard to Reach Populations”*. Invited talk at the 10th Annual Meeting of the CFAR Social and Behavioral Sciences Research Network. Miami, FLA. October 20, 2016.

- * *“The HIV Care Continuum”*. Invited Talk at the Symposium on Clinical and Prevention Care organized by the Fulton County Department of Health and Wellness. Atlanta, Ga. June 20, 2016.
- * *“High Impact Research Transforming Health Policy”*. HIV Grand Rounds organized by the Univ. of Pennsylvania CFAR. Philadelphia, Penn June 16, 2016.
- * *“High Impact Research Transforming Health Policy”*. Invited talk at the 3rd Annual “Advancing Healthcare Quality Research at Emory University: Symposium. Atlanta, Ga. May 18, 2016.
- * *“Improving retention and viral suppression among hard-to-reach HIV-infected populations”*. University of Miami CFAR Visiting Professor. Miami, Fla. May 5th, 2016.
- * *“Sexual Transmission and Mosquitoes: A New Phenomenon in Arbovirology?”* Bridging the Sciences: Zika Virus. Atlanta, GA May 1 – 2, 2016.
- * *“Global Health and US Universities”*, invited speaker at the University of South Carolina Global Health Initiative Workshop. Columbus, SC Oct 22 -23, 2015.
- * *“Becoming an investigator: From Medicine Resident to Professor of Medicine and CFAR co-Director”*, invited lecture at the NIAID/IDSA Infectious Diseases Careers Meeting 2015. Bethesda, MD June 4 – 6, 2015.
- * *“Tactical decision making in Health and Humanitarian Supply Chain Management”*. Invited lecture at the Georgia Tech course “Health & Humanitarian Supply Chain Management”. May 14th, 2015.
- * *“Ebola and other Global Issues of Local Concern”*. Invited talk at the 2015 Infectious Diseases Association of California (IDAC) Spring Symposium. Costa Mesa, CA May 2-3, 2015.
- * *“The Ebola Crisis: Lessons in International Cooperation for Global Health”*. Invited talk at the Association of Academic Health Centers 2015 International Forum. Washington, DC April 20 - 21, 2015.
- * Keynote speaker *“What will it take to end the AIDS epidemic?”*. Invited talk at the HIV Drug Therapy in the Americas Congress 2015. Mexico City, MEX. April 16 – 18, 2015.
- * Keynote Address at the 12th Annual Graduate Division of Biological and Biomedical Sciences Student Research Symposium. Emory University School of Medicine. Jan 15th, 2015.
- * *“How Far We’ve Come and How Far We Still Need to Go: Engagement in HIV Care for our Most Vulnerable Populations of People Living with HIV in Atlanta and the Southern United States”*. Invited talk at the 16th World AIDS Day Symposium organized by the UNC Center for AIDS Research and the Institute for Global Health and Infectious Diseases. Dec 5th, 2014.
- * *“The Past, Present, and Future of Global Health Engagement by Academic Institutions”*. Keynote Lecture at the CFAR HIV Research in International Settings (CHRIS) Meeting hosted by the UCSD CFAR. Oct 1st, 2014.
- * *“Advances in Seek, Test and Treat Strategies/Treatment as Prevention”*. Invited talk at the US-Georgia Program Development Workshop on HIV/AIDS, Tuberculosis and Hepatitis. Tbilisi, Georgia. June 16 – 18, 2014.
- * *“The Diagnosis and Treatment of HIV infection: Translating research into policy and practice”*. Invited talk at the 7th Anniversary of CISIDAT (Consortio de Investigacion sobre VIH/SIDA/TB). Mexico City, Mex. June 5, 2014.

- * *“Can we end the HIV epidemic”*. Life of the Mind Lecture Series organized by the Provost of Emory University. March 26, 2014.
- * *“Linkage and Retention: What works and what doesn’t”*. Invited talk at the 4th International HIV Workshop on Treatment as Prevention. Vancouver, BC. April 1 – 4, 2014.
- * *“Challenges in the HIV Continuum of Care and its Relevance to Treatment as Prevention”*. University of Miami CFAR Visiting Professor. February 28, 2014.
- * *“Current Status of HIV Continuum of Care Research”*, Invited Talk at the 2nd National CFAR/APC HIV Continuum of Care Working Group Meeting: Implementation Science to Address the Challenges of the HIV Continuum of Care. Washington, DC. Feb 3 – 4, 2014.
- * *“The Fight Against AIDS”*, Invited TEDx Talk at Institut LeRosey, Switzerland. Nov 9, 2013 (<http://tedxtalks.ted.com/video/The-Fight-Against-AIDS-Dr-Carlo> & <http://www.youtube.com/watch?v=F2Hz4t66-Ig>)
- * *“Seek, Test, Treat and Retain Among Vulnerable Populations”*, Invited Speaker to the Spring Meeting of the Massachusetts Infectious Diseases Society. Boston, Mass May 14, 2013.
- * *“Treatment is Prevention: novel approaches to HIV therapy”*, Key Note Speaker, AIDS United Access to Care Grantee Meeting, Atlanta, GA April 5, 2012.
- * *“The Future of HIV Prevention”*, Key Note Speaker at the 5th Research Meeting on HIV/AIDS diagnosis, care and prevention among vulnerable populations. Mexico City, Mexico. November 14, 2011
- * *“History of HIV/AIDS in the US”*, Speaker at the 2011 American Conference for the Treatment of HIV (ACTHIV). Denver, CO. April 7, 2011.
- * *“Building on Success”*. Speaker at the CDC World AIDS Day Event. Atlanta, GA. December 1, 2010
- * Invited Keynote speaker: *“Evidence Based Global Health”*. Annual Meeting of the Mexican National Epidemiological Surveillance System (Reunion Nacional del Sistema Nacional de Vigilancia Epidemiologica). Cancun, Mex. November 22, 2010
- * Invited Keynote address: *“Recent Advances in Biomedical HIV Prevention: Translating Research into Practice”*. 5th National Scientific Meeting of the CFAR’s Social and Behavioral Sciences Research Network. Atlanta, GA. October 8, 2010
- * *“14th Annual Paul J. Galkin Lectureship”* Brown University, Providence, RI. September 20-21, 2010.
- * *“University of Massachusetts Center for Global Health Visiting Professor”* University of Massachusetts, Worcester, MA. May 19, 2010
- * *“Facilitators and Barriers to HIV testing in hospital and other ambulatory care settings”*. Presentation to the Institute of Medicine Workshop to identify facilitators and barriers to HIV testing. Washington DC. April 15, 2010.
- * *“Tim Gills Visiting Professorship”* University of Colorado at Denver Center for AIDS Research, Denver CO. March 30-31, 2010.
- * *“Viral Zip Codes: Novel Influenza A (H1N1): what have we learned in the last 6 months?”* Invited speaker at the Fifth Annual National Symposium on Predictive Health “Human Health: Molecules to Mankind”. Atlanta, GA. December 14, 2009
- * *“Public Health and Health Care: Working Together for HIV Prevention”*. Discussant in CDC Panel for World AIDS Day. Atlanta, GA. December 1, 2009

- * *“The Healthcare needs of Migrants*. Key Note Speaker at the Hispanic Health Coalition of Georgia Latino Health Summit. Atlanta, GA. February 27, 2009.
- * *“Challenges in improving the National Response to the HIV/AIDS Epidemic”*. Invited Speaker at the Seminar organized by the Instituto Nacional de Salud Publica and the Secretaria de Salud, Mexico. February 20, 2009
- * *“Challenges and Controversies in Infectious Diseases in the XXI Century”*. Invited Lecture at the XXI Annual Meeting of the Medical Society of Hospital Angeles, Mexico City, Mex. February 19, 2009
- * *“Antiretroviral Therapy: 25 years of Progress”*. Medical Grand Rounds, SUNY Downstate Medical Center, Brooklyn NY. December 11, 2008
- * *“Confronting the Global HIV epidemic: moving forward after Mexico City”*. Invited key note speaker to the Second Annual International; HIV/AIDS Research Day of the UCSD CFAR. San Diego, CA. October 7, 2008
- * *“In the Eye of the Storm: The Emerging Epidemics of HIV, Hepatitis and Tuberculosis in the Former Soviet Republic of the Caucasus”*. Invited Global Health Institute seminar speaker, University of North Carolina, Chapel Hill, NC. December 8, 2007.
- * *“Strategies for Initial Antiretroviral Therapy through Complicated Failure: A Case-Based Discussion”*. Lecture presented at the Annual IAS-USA Course Improving the Management of HIV Disease. New York, NY. October 19, 2007
- * *“New Antiretrovirals”*. Lecture presented at the Annual IAS-USA Course Improving the Management of HIV Disease. Washington, DC. May 23, 2007.
- * *“Antiretroviral Therapy Failure: A case based discussion”*. Lecture presented at the Annual IAS-USA Course Improving the Management of HIV disease. Atlanta, GA. April 27, 2007.
- * *“The Perfect Storm: Emerging Epidemics of HIV, HCV and TB in the Republics of the Former Soviet Union”*. Invited Lecture in the course: AIDS: A Multidisciplinary Approach” at the University of Washington. Seattle, WA. April 2, 2007
- * *“Strategies for Recruitment of Minority Study Participants”*. Invited lecture presented at the symposium “Ethics in Action: Building Trust and Effectiveness in the Clinical Trial Process – Are we doing our best? Organized by the Emory University School of Medicine Clinical Trials Office and the Emory Center for Ethics. Atlanta, GA. March 1, 2006.
- * *“Antiretroviral Therapy in the Treatment Experienced Patient”*. Lecture Presented at the 13th Annual IAS-USA Current challenges in HIV disease. New York, NY. October 17, 2005.
- * *“Update in HIV infection”*. Lecture presented at the Northside Hospital Internal Medicine Conference. Atlanta, GA. September 8, 2005.
- * *“Strategies for Providing Care to Hard to Reach Populations”*. Invited Lecture and visiting Professorship at the University of North Carolina, Chapel Hill, NC. June 9 -10, 2005.

Invitations to National or International Conferences: (last ten years)

- *“Linkage to Care”* Plenary Speaker at ANAC2016. Atlanta, GA. Nov 10 – 12, 2016
- *“What’s Hot in HIV Clinical Research”*. Invited speaker at IDWeek2016. New Orleans, LA. Oct 26 – 30, 2016
- *“What’s New, What’s Next, What’s Ahead?”* Invited Plenary Speaker at AIDS2016.

Durban, South Africa. July 17 – 22, 2016.

- “*Meeting the Health Care Workforce Challenge*”, Invited speaker at the 2016 Pre-Conference UN 90-90-90 Target Workshop. Durban, South Africa. July 17, 2016.
- “*Diagnosis and management of Zika infected and exposed pregnant women*”, Invited talk at the XXI Congreso Mexicano de Especialistas en Ginecología y Obstetricia, A.C. Mexico City, Mex. June 23, 2016.
- “*Interactive Cases: Infectious Diseases in Travelers*”, Invited speaker at the XLI Congress of the Mexican Infectious Diseases Society. Monterrey, Mex. May 25 – 28, 2016.
- “*Optimizing Adherence to Antiretroviral Therapy: Current and Future Options*”, Invited speaker at IDWeek2015. San Diego, Calif. Oct 7 – 11, 2015.
- “*Update on vaccines for HIV-infected Patients*”, Invited speaker at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC Sept 5 – 9, 2014.
- “*Infectious Diseases in the context of Global Health*”, Invited Plenary Speaker at the XXXIX Congress of the Mexican Infectious Diseases Society. Acapulco, Mex. May 28 – 31, 2014.
- “*HIV Prevention 2013*”, Invited Plenary Speaker at the 26th Annual Conference of the Association of Nurses in AIDS Care (ANAC). Atlanta, GA November 22, 2013
- “*Vaccines in Immunocompromised patients*”, Invited Speaker at the 4th International Workshop on HIV & Aging. Baltimore, MD Oct 31, 2013
- “*Addressing the Gaps in the HIV Care Cascade*”. Invited talk at the “Treatment as Prevention and Pre-Exposure Prophylaxis Summit”. London, UK. Sept 22 – 24, 2013.
- “*Early Diagnosis and Treatment of HIV Infection*”, Invited talk at the 15th International Symposium on HIV/AIDS of the Mexican Infectious Diseases Society. Queretaro, Mex. Aug 29 – 31, 2013.
- “*Confronting the challenge of infectious diseases among substance abusers*” Invited Conference at the XIII Congress of the Argentinian Society for Infectious Diseases. Mar del Plata, Argentina. June 9 – 11, 2013
- “*Biomedical HIV Prevention*” Invited Conference at the XIII Congress of the Argentinian Society for Infectious Diseases. Mar del Plata, Argentina. June 9 – 11, 2013
- “*Introduction to Global Health*”. Invited Speaker to Lab Medicine 2013. 48th Annual Meeting of the Academy of Clinical Laboratory Physicians & Scientists. Atlanta, GA June 6 – 8, 2013
- “*How Should We Spend our Prevention Dollars?* Invited Speaker to the 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA March 3 – 6, 2013
- “*Opportunistic Infections in Patients with HIV Infection*” and “*The Pregnant Patient with HIV*”. Invited Speaker at the 39th Remington Winter Course in Infectious Diseases. Beaver Creek, CO. February 10 – 15, 2013
- “*The Importance and Implications of Antibiotic Resistance for the Clinician*”. Keynote Speaker at the VII Congreso Grupo Angeles. Mexico City, Mex. Oct 25 – 27, 2012.
- “*Adherence and Retention in Care*”. Invited Speaker to the AWACC (Annual Workshop on Advanced Clinical Care) – AIDS 2012 Conference. Durban, South Africa. October 5, 2012.
- “*Antiretroviral Therapy as Prevention: A Debate on the Role of ART as Prevention in*

Clinical Practice". Open Plenary Speaker at the 2012 American Conference for the Treatment of HIV (ACTHIV), Denver, CO. May 10 -12, 2012,

- “*Aging and HIV: Update from CROI*”. Invited Speaker at the 5th International Course HIV: Pathogenesis, Prevention and Treatment. Lima, Peru. March 23 – 24, 2012.
- “*Neurological Complications of HIV Infection*” and “*Clinical Spectrum of Acute Retrovirus Syndrome*”. Invited Speaker at the 37th Remington Winter Course in Infectious Diseases. Snowmass, CO. February 6 – 11, 2011
- “*Retention in Care*”. Invited Speaker at the 48th Annual Meeting of the Infectious Diseases Society of America Vancouver, Canada. October 21-24, 2010
- “*HIV infection – beginning HAART*” and “*HIV infection – Managing opportunistic infections*”. Invited Speaker at the 36th Remington Winter Course in Infectious Diseases. Vail, CO. February 21 – 26, 2010
- “*HIV Prevention among hard to reach populations*”. United States-Russia Workshop on HIV Prevention Science organized by the Office of AIDS Research. Moscow, Russia. October 28 – 30, 2009.
- “*The role of Integrase inhibitors in the treatment of HIV infection*”. Invited speaker at the 9th International Symposium of the Mexican Association of HIV Providers (AMMVIH). Cancun, Mex. November 22, 2008
- “*Current Issues and Controversies in HIV Infection Management*” Invited panelist to an Interactive Symposium at the 48th Annual ICAAC/46th Annual IDSA. Washington, DC. October 27, 2008
- “*HIV, STDs and the Global AIDS Pandemic: Lethal Synergy 2008*” Invited panelist to an Interactive Symposium at the 48th Annual ICAAC/46th Annual IDSA. Washington, DC. October 28, 2008
- “*Treating Tuberculosis in People Living with HIV*”. Invited Plenary Speaker at the Second Eastern Europe and Central Asia AIDS Conference. Moscow, Russian Federation, May 3 – 5, 2008.
- Poster discussant in the session “*New approaches to HIV testing*” at the 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA. February 4, 2008.
- “*New drugs and old challenges in AIDS*”. Invited plenary speaker at the X Mexican National HIV/AIDS Meeting. Leon, Mex. December 1, 2007.
- “*The Metamorphosis of the HIV Epidemic*”. Invited lecture presented at the XXIV National Congress of Biomedical Research in Mexico. Monterrey, NL. Mex. Aug 30, 2007
- “*Management of HIV Infection*”. Invited panelist to an Interactive Symposium at the 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Canada. October 13, 2006
- “*Yellow fever: New Challenges to an Old Scourge*”. Invited lecture presented at the Annual Meeting of the Binford-Dammin Society of Infectious Disease Pathologists. Atlanta, GA. February 12, 2006.
- “*Antiretroviral Therapy and its impact on Public Health*”. Invited speaker at the XI National Public Health Congress. Cuernavaca, Mex. March 2, 2005.
- “*Screening for HIV in Emergency Departments*”. Invited lecture presented at the 2005 National HIV Prevention Conference. Atlanta, GA. June 13, 2005.

Bibliography:a. Published and accepted research articles in refereed journals:

1. Gallo S, Marin E, Ramírez A, **del Río C**, Elizondo J, Ramírez J. Colocación Endoscópica de Sondas para Alimentación Enteral. Rev. Gastroenterol Mex. 1984; 49(4): 247-50 [PMID 6442452].
2. Guarner J, **del Río C**, Slade BA. Tuberculosis as a Manifestation of the Acquired Immunodeficiency Syndrome. JAMA 1986; 256(22):3092. [PMID [3783842](#)]
3. **del Río C**, McGowan J. Severe diarrhea in pneumococcal bacteremia: croupous colitis. JAMA 1987; 257(2): 189 [PMID 3795402].
4. Levy D, **del Río C**, Stephens DS. Meningococemia in identical twins: changes in serum susceptibility after rifampin chemoprophylaxis. J Infect Dis 1988; 157:1064-8 [PMID 3129520].
5. **del Río C**, Guarner J, Honig EG, Slade BA. Sputum examination in the diagnosis of *Pneumocystis carinii* pneumonia in the acquired immune deficiency syndrome. Arch Pathol Lab Med 1988; 112:1229-1232 [PMID 3142440].
6. Mirra SS, **del Río C**. The fine structure of AIDS encephalopathy. Arch Pathol Lab Med 1989; 113:858-65. [PMID 2757485]
7. **del Río C**, Stephens DS, Knapp JS, Rice RJ, Schalla WO. Comparison of isolates of *Neisseria gonorrhoeae* causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency. J Clin Microbiol 1989; 27(5): 1045-49 [PMID 2473091/PMC 267480].
8. Guarner J, **del Río C**, Williams P, McGowan JE. Fungal peritonitis caused by *Curvularia lunata* in a patient undergoing peritoneal dialysis. Am J Med Sci 1989; 298 (5): 320-23 [PMID 26837770].
9. **del Río C**, Soffer O, Widell JL, Judd RL, Slade BA. Acute Human Immunodeficiency virus infection temporally associated with rhabdomyolysis, acute renal failure and nephrosis. Rev. Infect Dis 1990; 12(2): 282-85 [PMID 2330481].
10. Guarner J, **del Río C**, Hendrix L, Unger ER. Composite Hodgkin's and non-Hodgkin's lymphoma in a patient with AIDS. In situ demonstration of Epstein-Barr Virus. Cancer 1990; 66(4): 796-800 [PMID 2167145].
11. Beciewicz PA, **del Río C**, Goncalves MA, Lattouf OM, et al. Catastrophic thrombosis of porcine aortic bioprosthesis. Ann Thorac Surg 1990; 50: 817-9 [PMID 2241350].
12. Guarner J, **del Río C**, Carr D, Hendrix LE, Eley JW, Unger ER. Non-Hodgkin's lymphomas in patients with HIV infection: Presence of Epstein - Barr virus by "in-situ" hybridization. Clinical Presentation and Follow-up. Cancer 1991; 68: 2460-65 [PMID 1657357].
13. Majluf-Cruz AS, Hurtado R, Mijangos C, Souto C, **del Río C**, Simón J. Síndrome Hemofagocítico en Asociación a Histoplasmosis en el Síndrome de Inmunodeficiencia Adquirida: descripción de tres casos y revisión de la literatura. (Haemophagocytic syndrome associated to histoplasmosis in AIDS: report of three cases). Sangre 1993; 38(1): 51-55 [PMID 8470036].
14. **del Río C**, Téllez I. Ganancia de peso con el uso del acetato de megestrol (Megace^R) en pacientes con SIDA y pérdida de peso en México. (Weight gain with the use of Megace^R in Mexican patients with AIDS). Enf Infecc y Microbiol 1993; 13(5): 249-52.
15. Guarner J, Izazola J, **del Río C**. Los problemas de conteo células T CD4+. (Problems in CD4+ T-cell count). Rev Invest Clin 1994; 46:163-4 [PMID 7914377].

16. Souto-Meriño CA, Simón-Domínguez J, Pulido-Priego MA, Hernández-Pérez A, García-Hernández IC, **del Río C**. Prevalencia de Marcadores para Hepatitis A, B y C en un Hospital de México. (The Prevalence of markers for hepatitis A, B and C in a hospital in Mexico). *Salud Públ Mex* 1994; 36:257-262 [PMID 7940005].
17. Izazola JA, Valdez M, Sánchez HJ, **del Río C**. Mortalidad por el Síndrome de Inmunodeficiencia Adquirida (SIDA) en México de 1983 a 1992. Tendencias y años perdidos de vida potencial. (AIDS mortality in Mexico, 1983 to 1992. Trends and years of potential life lost). *Salud Públ Méx* 1995; 37:140-148 [PMID 7618114].
18. **del Río C**, Muñiz M, Mellado E, et al. Premarital HIV testing: the Case of Mexico. *AIDS & Public Policy Journal* 1995; 10(2): 104-106.
19. **del Río C**, Guarner J, Izazola JA. The use of oral fluid to determine HIV-1 prevalence rates among men in Mexico City. *AIDS* 1996; 10(2): 233-235 [PMID 8838717].
20. Uribe-Salas F, **del Río-Chiriboga C**, Conde C, Juárez-Figueroa L, Uribe-Zuniga P, Calderón –Jaimes E, Hernandez-Ávila M. Prevalence, incidence and determinants of syphilis in female commercial sex workers in Mexico City. *Sex Transm Dis* 1996; 23(2): 120-126 [PMID [8919738](#)].
21. **del Río-Chiriboga C** y Orzechowski A. Sarampión en adultos: características clínicas en 25 pacientes hospitalizados. (Measles in adults: characteristics of 25 hospitalized adults). *Enf Infec Microbiol* 1996; 16 (1): 12-15.
22. **del Río C**, Tellez I, Orzechowski A, Alanis A. The spectrum of HIV infection in patients seen at a private hospital in Mexico City: 115 patients seen from 1984 to 1990. *Arch Med Res* 1996; 27(2): 201-204 [PMID [8696065](#)].
23. Ponce de León S, **del Río C**, Rangel S, Magis C. Infección por VIH en trabajadores de la salud en México. (HIV infection in healthcare workers in Mexico). *SIDA-ETS* 1996; 2(1): 14-16.
24. Guarner J, Sánchez Mejorada G, **del Río C**, Mohar A. Simplificación en el conteo de linfocitos T-CD4 positivos en 500 personas con infección por VIH/SIDA en México. (A simplified CD4 T-lymphocyte cell count in patients with HIV/AIDS in Mexico). *Salud Públ Méx* 1996; 38(3): 207-211 [PMID 8757546].
25. Guarner J, Uribe-Zúñiga P, Hernández G, Terán X, **del Río C**. Comparison of CD4 positive T-cell counts in men and women recently diagnosed with HIV infection on Mexico City, Mexico. *AIDS* 1997; 11(5): 701-2 [PMID 9108965].
26. Hernández C, Uribe F, Conde C, Cruz A, Juárez L, Uribe P, **del Río C**, Hernández M. Seroprevalencias a diversos virus y características sociodemográficas en mujeres que buscan detectarse VIH (Seroprevalence of viruses and sociodemographic characteristics in women seeking HIV screening). *Revista de Investigación Clínica* 1997; 49(1):5-13 [PMID 9229756].
27. Juárez-Figueroa L, Uribe-Salas F, Conde-González C, Hernández-Avila M, Hernández-Nevárez P, Uribe-Zúñiga P, **del Río-Chiriboga C**. Hepatitis B markers in men with high risk sexual behavior in Mexico City. *Sexually Transm Dis* 1997; 24(4): 211-217 [PMID 9101632].
28. **del Río C**, Edupuganti S, Cassoobhoy M, et al. Malaria in an Immigrant and Travelers - Georgia, Vermont, and Tennessee, 1996. *MMWR* 1997; 46(23):536-539.
29. Uribe-Salas F, Conde-González C, Allen B, **del Río-Chiriboga C**, de Zalundo B, Hernández-Avila M, Juárez-Figueroa L, Anaya-Ocampo R, Uribe-Zúñiga P. Low HIV and STD Prevalence in a Random Sample of Female Commercial Sex Workers in

- Mexico City. *Amer J Pub Health* 1997; 87(6): 1012-15 [PMID 9224186/PMC 1380940].
30. Guarner J, Montoya P, **del Río C**, Hernández-Tepichin G. CD4+ T-Lymphocyte variations in Patients with Advanced HIV Infection and Counts Below 100 cells/ μ L. *Cytometry (Communic Clin Cytometry)* 1997; 30:178-80 [PMID 9298835].
 31. **del Río C**, Orzechowski A, Sánchez Mejorada G. Toxoplasmosis of the Central Nervous System in Patients with AIDS in Mexico. *Arch of Medical Research* 1997; 28(4):527-530 [PMID 9428578].
 32. **del Río-Chiriboga C**, Sánchez Mejorada G, Orzechowski A, Lanfranchi R, Esponda J, Robles M. El síndrome de inmunodeficiencia adquirida en la unidad de terapia intensiva del Hospital Angeles del Pedregal. (AIDS in the intensive care unit at Hospital Angeles). *Enf Infecc y Microbiol* 1997; 17(6): 156-159.
 33. Albrecht H, **del Río C**, Rimland D. Seminal viral load. *AIDS* 1998; 12(3):333-334 [PMID 95180003].
 34. **del Río C**, Kamarulzaman A, Schüklenk U. Ethics, Economic Realities and Medical Research in Developing Countries. *Repr Health Matters* 1998; 6(11): 135-6.
 35. Jurado R, **del Río C**, Nassar G, Navarrete J, Pimentel JL. The Low Anion Gap. *Southern Med J* 1998; 91(7):625-629 [PMID 9671832].
 36. Volkow P, Pérez R, **del Río C**, Mohar A. The role of commercial plasmapheresis facilities on the AIDS epidemic in Mexico. *Rev Invest Clin* 1998; 50(3): 221-226 [PMID 9763887].
 37. López C, Guarner J, Magis C, Uribe P, **del Río C**. Zidovudina más didanosina en pacientes asintomáticos infectados por VIH previamente tratados con zidovudina (Zidovudine plus didanosine in the treatment of HIV asymptomatic patients previously treated with zidovudine). *Rev Invest Clin* 1998; 50 (4): 335-339 [PMID 9830323].
 38. Rothenberg RB, Scarlett M, **del Río C**, Reznik D, O'Daniels C. Oral Transmission of HIV. *AIDS* 1998; 12:2095-2105 [PMID 9833850].
 39. Wilfert CM, Ammann A, Bayer R, Curran JW, **del Río C**, et al. Science, ethics, and the future of research into maternal infant transmission of HIV-1. *Lancet* 1999; 353:832-35.
 40. Beard CB, Carter JL, Keely SP, Hung L, Pieniazek NJ, Moura I, Freeman AR, Lee S, Stringer JR, Duchin JS, **del Río C**, Rimland D, Baughman RP, Levy DA, Dietz VJ, Simon P, Navin TR. Genetic Variation in *Pneumocystis carinii* Isolates from Different Geographic Regions: Implications for Transmission. *Emerg Inf Dis* 2000; 6(3): 265-272 [PMID 10827116/ PMC 26400877].
 41. Hung L, Beard CB, Creasman J, Levy D, Duchin JS, Lee S, Pieniazek N, Carter J, **del Río C**, Rimland D, Navin TR. Sulfa or Sulfone Prophylaxis and Geographic Region Predict Mutations in the *P. carinii* Dihydropteroate Synthase Gene. *J Inf Dis* 2000; 182:1192-8 [PMID 10979917].
 42. Bruce BB, Blass MA, Blumberg HM, Lennox JL, **del Río C**, Horburgh CR. Risk of *Cryptosporidium parvum* Transmission between Hospital Roommates. *Clin Infect Dis* 2000; 31:947-50 [PMID 11049775].
 43. Green S, **del Río C**. HIV pretest and posttest counseling: still missing from medical school curriculum. *Arch Intern Med* 2000; 160: 3326 [PMID 11088096].
 44. Albrecht H, Lennox JL, **del Río C**. Quinidine and Malaria. *Arch Intern Med* 2001; 161: 1118-1119 [PMID 11322855].

45. Fox KK, **del Rio C**, Holmes KK, Hook EW, Judson FN, Knapp JS, et al. Gonorrhea in the HIV Era: A reversal in Trends among Men who have sex with men. *Am J Publ Health* 2001; 91:959-964 [PMID 11392941/PMC 1446475].
46. **del Rio C**, Franco-Paredes C, Duffus W, et al. Routinely Recommended HIV Testing at an Urban Urgent-Care Clinic - Atlanta, GA 2000. *MMWR* 2001; 50(25): 538-541.
47. Navin TR, Beard CB, Hung L, **del Rio C**, Lee S, Pieniazek NJ, Carter JL, Lee T, Hightower A, Rimland D. Effect of Mutations in the *Pneumocystis carinii* dihydropteroate synthase gene do not affect outcome of *P. carinii* pneumonia in HIV-infected patients. *Lancet* 2001; 358: 545-549 [PMID 11520525].
48. Blumberg H & **del Rio C**. Management of Tuberculosis (correspondence). *New Engl J Med* 2001; 345(20):1501 [PMID 11794210].
49. Eichler M, **del Rio C**, Ray S. The Effectiveness of HIV post-test counseling in determining healthcare seeking behavior. *AIDS* 2002; 16(6): 943-945 [PMID 11919504].
50. Nimri L, Moura IN, Huang L, **del Rio C**, Rimland R, Duchin J, Dotson E, Beard CB. Genetic Diversity of *Pneumocystis carinii* f. sp. *hominis* Based on Variations in Nucleotide Sequences of Internal Transcribed Spacers of rRNA Genes. *J. Clin Microbiol* 2002; 40(4):1146-1151 [PMID 11923323/PMC 140386].
51. Hernández –Girón C, Tovar V, **del Rio C**. AIDS Mortality in Mexico, 1988 – 1997. *Salud Publica de Mexico* 2002; 44: 207 – 212 [PMID 12132317].
52. **del Rio C**, Sepúlveda J. AIDS in Mexico: lessons learned and implications for developing countries. *AIDS* 2002; 16: 1445 – 1457 [PMID 12131182].
53. DiClemente R, Wingood GM, **del Rio C**, Crosby RA. Prevention Interventions for HIV-Positive Individuals: A Public Health Priority. *Sex Trans Inf* 2002; 78:393-395 [PMID 12473796].
54. Franco-Paredes C, Guarner J, Mehrabi D, McCall C, **del Rio C**. Clinical and Pathological Recognition of Leprosy. *Am J Med* 2003; 114:246-47 [PMID 12637144].
55. Duffus WA, Barragán M, Metsch L, Krawczyk CS, Loughlin AM, Gardner LI, Anderson-Mahoney P, Dickinson G, **del Rio C**. Effect of Physician Specialty on Counseling Practices and Medical Referral Patterns for Physicians Caring for Disadvantaged HIV-infected Populations. *Clin Infect Dis* 2003; 36:1577-84 [PMID 12802759].
56. Rothenberg R, Campos P, **del Rio C**, Johnson W, Jacob Arriola K, Brown M. Once and Future Treatment: A comparison of Clinic and Community Groups. *Int J of STD & AIDS* 2003; 14(7): 438-447 [PMID 12869222].
57. Tobin M, Blass M, **del Rio C**, Havlosa S, Blumberg H, Horsburgh CR. Hospital water as a source of *Mycobacterium avium* complex (MAC) isolates in respiratory specimens. *J Infect Dis* 2004; 189:98-104 [PMID 14702159].
58. Hutchinson AB, Corbie-Smith G, Thomas S, Mohanan S, **del Rio C**. Understanding the Patients Perspective on Rapid and Routine HIV Testing in an Inner-City Urgent Care Center. *AIDS Education and Prevention* 2004; 16(2):101-114 [PMID 15154119].
59. Zaller N, Nelson K, Aladashvili M, Badridze N, **del Rio C**, Tsertsvadeze T. Risk Factors for Hepatitis C virus infection among Blood donors in Georgia. *Eur J Epidemiol* 2004; 19:547-553 [PMID 15330127].
60. Metsch LR, Pereyra M, **del Rio C**, Gardner L, Duffus W, Dickinson G, Kerndt P, Anderson-Mahoney P, Strathdee S, Greenberg A. The Delivery of HIV Prevention Counseling by Physicians at HIV Medical Care Settings in Four US Cities. *Am J Publ*

- Health 2004; 94:1186-1192 [PMID 15226141/PMC 1448419].
61. Valverde E, **del Rio C**, Metsch L, et al. Characteristics of Ryan White and Non-Ryan White-Funded HIV Medical Care Facilities across Four Metropolitan Areas. Results from the ARTAS Site Survey. *AIDS Care* 2004; 16(7): 841-850 [PMID 15385239].
 62. **del Rio C**, Barragan M, Franco-Paredes C. Pneumocystis Pneumonia (correspondence). *New Engl J Med* 2004; 351(12):1262 -3 [PMID 15371588].
 63. Vicas A, Albrecht H, Lennox JL, **del Rio C**. Imported Malaria at an inner-city Hospital in the United States. *Am J Med Sci* 2005; 329(1): 6-12 [PMID 15654173].
 64. Tkeshelashvili-Kessler A, **del Rio C**, Nelson K, Tsertsvadze T. The Emerging HIV/AIDS Epidemic in Georgia. *Int J of STD & AIDS* 2005; 16(1): 61-67 [PMID 15705276].
 65. Volkow P, **del Rio C**. Paid donation and plasma trade: unrecognized forces that drive the AIDS epidemic in developing countries. *Int J of STD & AIDS* 2005; 16(1): 5-8 [PMID 15705264].
 66. Leonard MK, Osterholt D, Kourbatova EV, **del Rio C**, Wang W, Blumberg HM. How many sputum specimens are necessary to diagnose pulmonary tuberculosis? *Am J Infect Control* 2005; 33:58-61 [PMID 15685138].
 67. Priddy, F, Tasfaye F, Mengistu Y, Rothenberg R, Fitzmaurice D, Mariam, DH, **del Rio C**, Oli K, Worku A. Potential for Medical Transmission of HIV in Ethiopia. *AIDS* 2005; 19 (3): 348-350 [PMID 15718849].
 68. Franco-Paredes C, Rodriguez A, **del Rio C**. Lepromatous Leprosy. *Infections in Medicine* 2005; 22(5): 229.
 69. Gardner LI, Metsch LR, Anderson-Mahoney P, Laughlin AL, **del Rio C**, Strathdee S, Samsom SL, Siegal HA, Greenberg AE, Holmberg SD. Efficacy of a case management intervention to link recently diagnosed HIV-infected person to care. *AIDS* 2005; 19: 423-431. [PMID 15750396]
 70. Beckwith CG, Flanigan TP, **del Rio C**, Simmons E, Wing EJ, Carpenter CCJ, Bartlett JG. It is Time to Implement Routine, Not Risk-Based HIV Testing. *Clin Infect Dis* 2005; 40:1037-40 [PMID 15824997].
 71. Rudy E, Mahoney-Anderson P, Loughlin A, Metsch L, Kerndt P, Gaul Z, **del Rio C**. Perceptions of HIV Testing Services among HIV-positive Persons not in Medical Care. *Sex Transm Dis* 2005; 32(4): 207-21 [PMID 15788917].
 72. Barragán M, Hicks G, Williams M, Franco-Paredes C, Duffus W, **del Rio C**. Low Health Literacy is Associated with HIV Test Acceptance. *Journal of Gen Intern Med* 2005; 20 (5): 422-425.[PMID 15963165/PMC1490105]
 73. Cassoobhoy M, Wetterhall SF, Collins DF, Cantey PT, Iverson CJ, Rudnick JR, **del Rio C**. Bridging the gap between clinicians and public health through the development of an interactive bioterrorism and emerging infections curriculum for medical students and internal medicine residents. *Publ Health Reports* 2005; 120 (suppl 1): 59-63. [PMID 16025708/PMC 2569989]
 74. Rimland D, Guest JL, Hernandez I, **del Rio C**, Anh Le N, Brown WV. Increased ApoCIII to Triglyceride Ratios in HIV Positive Men on Antiretroviral Therapy. *HIV Medicine* 2005; 6: 326-333. [PMID 16156880]
 75. Silk B, **del Rio C**, Kim Ivansco L, Wetterhall S, Augustine J, Blumberg HM, Berkelman R. Pre-event Willingness to receive smallpox vaccine among physicians and public safety personnel. *Southern Med Journal* 2005; 98 (9):876-882 [PMID 16217979].

76. Beard CB, Fox MR, Lawrence GG, Guarner J, Hanzlick RL, Huang L, **del Rio C**, Rimland D, Duchin JS, Colley DG. Genetic Differences in *Pneumocystis* Isolates from Immunocompetent Infants and from Adults with AIDS: Epidemiological Implications. *Journal of Infect Dis* 2005; 192:1815-8 [PMID 16235182].
77. Nicholls DJ, King M, Holland D, Bala J, **del Rio C**. Intracranial Tuberculomas Developing while on Therapy for Pulmonary Tuberculosis. *Lancet Infect Dis* 2005; 795 – 801 [PMID 16310151].
78. Beckwith CG, Flanigan TP, **del Rio C**, Bartlett JG. Screening for HIV (Letter to the Editor). *Annals of Intern Med* 2005; 143:916.
79. Moanna A, Bajaj R, **del Rio C**. Emphysematous cholecystitis due to *Salmonella derby*. *Lancet Infect Dis* 2006; 6:118-120. [PMID 16439332]
80. Richards DC, Mikiashvili T, Parris JJ, Kourbatova EV, Wilson JC, Shubladze N, Tsertsvadze T, Khechinashvili G, **del Rio C**, Blumberg HM. High Prevalence of Hepatitis C Infection but not HIV co-infection among patients with Tuberculosis in the Republic of Georgia. *Int J TB and Lung Dis* 2006; 10(4): 1-6. [PMID 16602403]
81. Leonard MK, Egan KB, Kourbatova E, White N, Parrott P, **del Rio C**, Blumberg HM. Increased efficiency in evaluating patients with suspected pulmonary tuberculosis by use of a dedicated airborne infection isolation unit. *Am J Infect Cont* 2006; 34: 69-72. [PMID 16490609].
82. Whitney EA, Heilpern KL, Woods CW, Bahn CC, Franko EA, **del Rio C**, Silk BJ, Ratcliff JJ, Bryant KA, Park MM, Watkins SJ, Caram LB, Blumberg HM, Berkelman RL. West Nile Virus Infection among Hospitalized Febrile Patients: a case for expanding diagnostic testing. *Vector Borne and Zoonotic Diseases* 2006; 6(1): 42 – 49. [PMID 16584326]
83. Stvilia K, Tsertsvadze T, Sharvadze L, Aladashvili M, **del Rio C**, Kuniholm MH, Nelson KE. Prevalence of Hepatitis C, HIV, and Risk Behaviors for Blood-Borne Infections: A population-based study of the adult population of Tbilisi, Republic of Georgia. *J Urban Health* 2006; 83 (2): 289 – 298. [PMID 16736377/PMC 2527157]
84. Shapatava E, Nelson KE, Tsertsvadze T, **del Rio C**. Risk Behaviors and the Transmission of HIV, Hepatitis B and Hepatitis C among Injecting Drug Users in Georgia. *Drug and Alcohol Dependence* 2006; 82 (suppl 1): S35 – S38. [PMID 16769443]
85. Rimland D, Guest JL, Hernandez-Ramos I, **del Rio C**, Le AN, Brown WV. Antiretroviral Therapy in HIV Positive Women is Associated with Increased ApoCIII and Total Cholesterol. *J Acquir Immune Def Synd* 2006; 42: 307 – 313. [PMID 16770290]
86. Valverde E, Waldrop-Valverde D, Anderson-Mahoney P, Loughlin A, **del Rio C**, Metsch L, Gardner L. System and Patient Barriers to Appropriate HIV Care for Disadvantaged Populations: the HIV Medical Care Provider Perspective. *Journal of the Association of Nurses in AIDS Care* 2006; 17(3): 18-28. [PMID 16829359]
87. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, **del Rio C**, Kamimoto L, Kellermann SE. The Economic Burden of HIV in the US in the Era of Highly Active Antiretroviral Therapy: Evidence of Continuing Racial and Ethnic Differences. *JAIDS* 2006; 43: 451 – 457. [PMID 16980906]
88. Hicks G, Barragán M, Franco-Paredes C, Williams M, **del Rio C**. Health Literacy is a Predictor of HIV/AIDS Knowledge Level. *Family Medicine* 2006; 38(10): 717-23. [PMID 17075745]
89. Kourbatova K, Leonard M, Romo J, Kraft C, **del Rio C**, Blumberg HM. Risk Factors for

- Mortality among patients with intrapulmonary tuberculosis at an academic inner-city hospital in the US. *European J Epidemiol* 2006; 21(9): 715-21. [E-pub Oct 27, 2006] [PMID 17072539]
90. Kourbatova K, Borodulin B, Borodulina E, Leonard M, **del Rio C**, Blumberg H. Risk factors for mortality among patients with newly diagnosed tuberculosis in Samara, Russia. *Int J TB & Lung Dis* 2006; 10(11): 1224-1230. [PMID 17131780]
 91. Markosyan KM, Babikian T, DiClemente RJ, Hirsch JS, Grigoryan S, **del Rio C**. Correlates of HIV Risk and Preventive Behaviors in Armenian Female Sex Workers. *AIDS and Behavior* 2007; 11(2): 325 – 34 (E-pub July 6th, 2006). [PMID 16823626]
 92. Anthony MN, Gardner L, Marks G, Anderson-Mahoney P, Metsch L, Valverde E, **del Rio C**, Loughlin A. Factors associated with use of HIV primary care among persons recently diagnosed with HIV: Examination of variables from the behavioral model of health-care utilization. *AIDS Care* 2007; 19(2): 195-202. [PMID 17364398]
 93. Kelley C, Hernandez-Ramos I, Franco-Paredes C, **del Rio C**. The Clinical and Epidemiologic Characteristics of Foreign Born Latinos with HIV/AIDS at an Urban Clinic in the Southeastern United States. *The AIDS Reader* 2007; 17: 73 – 88. [PMID 17323506]
 94. Priddy FH, Pilcher CD, Moore RH, Tambe P, Park MN, Fiscus SA, Feinberg MB, **del Rio C**. Detection of acute HIV in an urban HIV counseling and testing population in the United States. *JAIDS* 2007; 44(2): 196 - 202. [PMID 17312561]
 95. Brewer T, Zhao W, Pereira M, **del Rio C**, Loughlin A, Anderson-Mahoney P, Gardner L, Metsch L: ARTAS Study Group. Initiating HIV Care: Attitudes and Perceptions of HIV Positive Crack Cocaine Users. *AIDS and Behavior* 2007; 11(6): 879-904. [Epub ahead of print Feb 13th, 2007] [PMID 17295070].
 96. **del Rio C**, Hall G, Hook EW, Holmes KK, Whittington WLH, Judson FN, et al. *Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections*. *MMWR* 2007; 56(14): 333 – 336.
 97. Hirsch JS, Meneses S, Thompson B, Negroni M, Plancarte B, **del Rio C**. The inevitability of Infidelity: Sexual Reputation, Social Geographies, and Marital HIV Risk in Rural Mexico. *Am J Publ Health* 2007; 97 (6): 986 – 96 [Epub ahead of print Apr 26th, 2007] [PMID 17463368/PMC 1874214]
 98. Gardner LI, Marks G, Metsch LR, Loughlin AM, O'Daniels C, **del Rio C**, Anderson-Mahoney P, Wilkinson JD. Psychological and Behavioral correlates of entering care for HIV infection: The Antiretroviral Treatment Access Study (ARTAS). *AIDS Patient Care and STD* 2007; 21 (6): 418-25. [PMID 17594251]
 99. Wang SA, Harvey AB, Conner SM, Zaidi AA, Knapp JS, Whittington WLH, **del Rio C**, Judson FN, Holmes KK. Trends in antimicrobial resistance for *Neisseria gonorrhoeae* in the United States, 1988 – 2003: the increasing spread of fluoroquinolone-resistance. *Ann Intern Med* 2007; 147: 81-88. [PMID 17638718]
 100. Vargas-Infante Y, Guerrero L, Ruiz-Palacios G, Soto-Ramirez L, **del Rio C**, Carranza J, Dominguez-Cherit G, Sierra-Madero J. Improving Outcome of Human Immunodeficiency Virus Infected Patients in a Mexican Intensive Care Unit. *Arch Med Res* 2007; 38:827-833. [PMID 17923262]
 101. Kuniholm M, Mark J, Aladashvili M, Shubladze N, Khechinashvili G, Tsertsvadze T, **del Rio C**, Nelson K. Risk factor and algorithms to identify Hepatitis C, Hepatitis B

- and HIV infection in Tuberculosis patients in Georgia. *Intl J Infect Dis* 2008; 12 (1): 51-6. {E-pub 2007 Jul 23} [PMID 17644020/PMC 2649965].
102. Tellez I, Barragán M, Franco-Paredes C, Petraro P, Nelson K, **del Rio C**. *Pneumocystis jiroveci* infection in patients with AIDS in the Inner City: A Persistent and Deadly Opportunistic Infection. *Am J Med Sci* 2008; 335(3): 192-97 [PMID 18344692].
 103. Salomon MM, Smith MJ, **del Rio C**. Low educational level: a risk factor for sexually transmitted infections among commercial sex workers in Quito, Ecuador. *Intl J. STD & AIDS* 2008; 19:264 – 267 [PMID 18482947].
 104. Mirtskhulava V, Kempker R, Shields KL, Leonard MK, Tsertsvadze T, **del Rio C**, Salakaia A, Blumberg HM. Prevalence and Risk Factors for latent tuberculosis infection among health care workers in Georgia. *Int J Tuberc Lung Dis* 2008; 12(5): 513-519. [PMID 18419886/PMC 2742226].
 105. Frew PM, Archibald M, Martinez N, **del Rio C**, Mulligan MJ. Promoting HIV Vaccine Research in African American Communities: Does the Theory of Reasoned Action Explain Potential Outcomes of Involvement? *Challenge (Atlanta Ga)*. 2007;13(2):61-97. [PMID 20686675/ PMC2913490]
 106. Frew P, **del Rio C**, Clifton S, Hormes JT, Mulligan J. M. Factors influencing HIV vaccine community engagement in the urban South. *J Community of Health* 2008; 33:259-269 {Epub ahead of print Apr 4}, [PMID 18389351].
 107. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Muraqli-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, **del Rio C**, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. *Immunity* 2008 May;28(5):710-22. {Epub 2008 May 8} [PMID 18468462]
 108. Metsch L, Pereyra M, Messinger S, **del Rio C**, Strathdee SA, Anderson-Mahoney P, Rudy E, Marks G, Gardner L. HIV transmission Risk behaviors among HIV-infected persons who are successfully linked to care. *Clin Infect Dis* 2008; 47:577-584 [PMID 18624629].
 - Article selected for reprint as part of “2009 *Clinical Issues in HIV Medicine*”, published by the Infectious Diseases Society of America
 109. Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Jibuti T, Shubladze N, Kutateladze T, Khechinashvili G, **del Rio C**, Salakaia A, Blumberg HM. High Prevalence of Multidrug-Resistant Tuberculosis in Georgia. *Int J Inf Dis* 2008; 12:635 – 644. {E-pub ahead of print on May 29}, [PMID 18514008/PMC 2645041].
 110. Pulendran P, Miller J, Troy DQ, Akondy R, Moseley N, Laur O, Glidewell J, Monson N, Zhu T, Staprans S, Lee D, Brinton MA, Perelygin AA, Vellozzi C, Brachman P, Lalor S, Teuwen D, Eidex RB, Cetron M, Priddy F, **del Rio C**, Altman J, Ahmed R. Case of Yellow Fever Vaccine-Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses and Polymorphisms in CCR5 and Rantes Genes. *J Infect Dis* 2008; 198: 500-507 [PMID18598196/PMC 3734802].
 111. Smith DJ, Wakasiaka S, Hoang TD, Bwayo JJ, **del Rio C**, Priddy FH. An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: Behaviors and attitudes that might influence uptake within a high-risk population. *Journal of Woman’s Health* 2008; 17(6): 1-10 [PMID 18681822/PMC 2942749].
 112. Kuniholm MH, Aladashvili, **del Rio C**, Stvilia K, Gabelia N, Chitale RA, Tsertsvadze T, Nelson KE. Not all Injection Drug Users are Created Equal: Heterogeneity of HIV,

- Hepatitis C Virus and Hepatitis B Virus Infection in the Republic of Georgia. Substance Use and Misuse 2008; 43: 1424-1437, [PMID 18696377/PMC2825388].
113. Gardner LI, Metsch L, Strathdee SA, **del Rio C**, Mahoney P, Holmberg SD for the ARTAS Study Group. Frequency of discussing HIV prevention and care topics with HIV-infected patients: Influence of physician gender, race-ethnicity and practice characteristics Gender Med 2008; 5(3): 259 – 269 [PMID 18727992]
 114. Shuster JM, Sterk CE, Frew P, **del Rio C**. The Cultural and Community-Level Acceptance of Antiretroviral Therapy (ART) Among Traditional Healers in Eastern Cape, South Africa. J of Community Health 2009; 34(1): 16-22 {e-pub ahead of print Oct 16, 2008} [PMID 18923887].
 115. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, **del Rio C**, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Carey L, Robertson MN, and the Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. The Lancet 2008; 372(9653):1881-93 {published online Nov 13, 2008} [PMID 19012954/PMC 2721012]
 116. Frew PM, Archibald M, Martinez N, **del Rio C**, Mulligan MJ. Promoting HIV Vaccine Research in African American Communities: Does the Theory of Reasoned Action Explain Potential Outcomes of Involvement? Challenge 2007; 13(2): 61-97. [PMID 20686675]
 117. Frew P, **del Rio C**, Lu Lu, Clifton S, Mulligan M. Understanding Differences in Enrollment Outcomes among High-Risk Populations in a Phase IIb HIV Vaccine Trial. JAIDS 2009; 50 (3): 214-391 [PMID 19194310].
 118. Kelley CF, Checkley W, Maninno DM, Franco-Paredes C, **del Rio C**, Holguin F. Trends in hospitalizations for AIDS-Related *Pneumocystis jirovecii* Pneumonia in the United States (1986 – 2005). Chest 2009; 36(1): 190-7. {epub ahead of print March 2} [PMID 19255292].
 119. Metsch LR, Bell C, Cardenas G, Pereyra M, Sullivan T, Rodriguez A, Gooden L, Khoury N, Kuper T, Brewer T, **del Rio C**. Hospitalized HIV-infected Patients: A Population of Concern in the Era of HAART. Am J Publ Health 2009, 99 (6): 1045-9. {epub ahead of print April 16} [PMID 19372520/PMC 2679801].
 120. Gardner L, Marks G, Craw J, Metsch L, Strathdee S, Anderson-Mahoney P, **del Rio C**. for the Antiretroviral Treatment Access Study Group. Demographic, psychological, and behavioral modifiers of the Antiretroviral Treatment Access Study Group. AIDS Patient Care & STD 2009; 23 (9): 1 – 8. {epub ahead of print Aug 2} [PMID 19645619].
 121. Schaffner J, Chochua S, Kourbatova EV, Barragan M, Wang YF, Blumberg HM, **del Rio C**, Walker HK, Leonard MK. High mortality among patients with positive blood cultures at the children's hospital in Tbilisi, Georgia. J Infect Dev Ctries 2009 May 1; 3(4): 267-72. [PMID 19759489/PMC 2864639]
 122. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Quyyumi F, Garg S, Altman JD, **del Rio C**, Keyserling HL, Ploss A, Rice C, Mulligan MJ, Orenstein WA, Ahmed R. The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T-cell Response. Journal Immunol 2009; {Epub ahead of print Nov 23} [PMID 19933869/PMC 3374958].

123. Asmuth DM, Brown EL, DiNubile MJ, Sun X, **del Rio C**, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quick EK, Mehrotra DV. Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Ad5, or Ad5/Ad5 HIV-1 Clade B *gag* Vaccine Prime-boost Regimens. *J Infect Dis* 2009 [Epub ahead of print Nov 24] [PMID 19929694].
124. Bell DM, Weisfuse IB, Hernandez-Avila M, **del Rio C**, Bustamante X, Rodier G. Pandemic influenza as 21st century urban health crisis. *Emerg Infect Dis* 2009; 15(12): 1963 – 9 [PMID 19961676/PMC 3044553]
125. Frew PM, Archibald M, Dixon Diallo D, Hou SI, Horton T, Chan K, Mulligan M, **del Rio C**. An Extended Model of Reasoned Action to Understand the Influence of Individual and Network-Level Factors on African American's Participation in HIV Vaccine Research. *Prev Sci* 2010; 11:207-218 {E-pub ahead of print Dec 12, 2009} [PMID 20012200; PMC2858782]
126. Esteves-Jaramillo A, Omer SB, Gonzalez-Diaz E, Salmon DA, Hixson B, Navarro F, Kawa-Karaski S, Frew P, Morfin-Otero R, Rodriguez Noriega E, Ramirez Y, Rosas A, Acosta E, Varela-Badillo V, **del Rio C**. Acceptance of a Vaccine Against Novel Influenza A (H1N1) Virus Among Health Care Workers in Two Major Cities in Mexico. *Arch Med Res* 2009; 40: 705-711 [PMID 20304260/PMC2854164]
127. Vogenthaler NS, Hadley C, Lewis S, Rodriguez A, Metsch L, **del Rio C**. Food Insufficiency among HIV-infected Crack Cocaine users in Atlanta and Miami. *Public Health Nutr* 2010 Jan 15:1-7 {Epub ahead of print Jan 15, 2010} [PMID 20074395/PMC 2973997].
128. Narayan KM & **del Rio C**. Comparative efficacy of influenza vaccines. *New Engl J Med* 2010; 362(2): 179-80. [PMID 20071712]
129. Vogenthaler NS, Hadley C, Rodriguez AE, Valverde EE, Metsch L, **del Rio C**. Depressive symptoms and food insecurity among HIV-infected crack users in Atlanta and Miami. *AIDS and Behavior* 2010; 15(7): 1520-6. {E-pub ahead of print Jan 23} [PMID 20099017/PMC2934749].
130. Zaragoza-Macias E, Cosco D, Nguyen M, **del Rio C**, Lennox JL. Predictors of success with highly active antiretroviral therapy in an antiretroviral naive urban population. *AIDS Res Hum Retroviruses* 2010; Feb;26(2):133-8 [PMID 20156096/PMC2858896].
131. Bell C, Metsch L, Vogenthaler N, Cardenas G, Rodriguez A, Locascio V, Kuper T, Scharf E, Marquez A, Yohannan M, **del Rio C**. Never in Care: Characteristics of HIV-infected crack cocaine users in two U.S. cities who never been to primary outpatient HIV care. *JAIDS* 2010; Aug 1; 54(4): 376-80. {Epub ahead of print Feb 18, 2010} [PMID 20173648/PMC2888612].
132. Frew PM, Hou SI, Davis M, Chan K, Horton T, Shuster J, Hixson B, **del Rio C**. The likelihood of participation in clinical trials can be measured: The Clinical Research Involvement Scales (CRIS). *Journal Clin Epidemiol.* 2010; 63: 110-1117. {Epub ahead of print March 18, 2010} [PMID 20303711/PMC2892193].
133. Crabtree-Ramirez B, Villasis-Keever A, Galindo-Fraga A, **del Rio C**, Sierra-Madero J. Effectiveness of Highly Active Antiretroviral Therapy (HAART) among HIV-infected patients in Mexico. *AIDS Res Human Retroviruses* 2010; 26 (4): 373 – 378. {E-pub ahead of print April 8} [PMID 20377418/ PMC 2933160].
134. Frew PM, Mulligan MJ, Hou, SI, Chan K, **del Rio C**. Time will tell: community

- acceptability of HIV vaccine Research before and after the “Step Study” vaccine discontinuation. *Open Access Journal of Clinical Trials* 2010; 2: 149 - 156. [PMID 21152413/PMC 2996614]
135. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey SM, McCausland M, Skoutzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, **del Rio C**, et al. Broadly cross-reactive antibodies dominate the acute B cell response against pandemic 2009 H1N1 influenza virus infection in humans. *J Exp Med* 2011, 208(1): 181-93. {Epub ahead of print Jan 10, 2011} [PMID 21220454/PMC 3023136]
 136. Hixson BA, Omer SB, **del Rio C**, Frew PM. Spatial Clustering of HIV Prevalence in Atlanta, Georgia and Population Characteristics Associated with Case Concentrations. *J Urban Health* 2011; {Epub ahead of print Jan 20} [PMID 21249526/PMC 3042078].
 137. Tsertsvadze T, Chkhartishvili N, Sharvadze L, Dvali N, Chokoshvili O, Gabunia P, Abutidze A, Nelson K, DeHovitz J, **del Rio C**. Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia. *AIDS Research and Treatment* 2011; 2011: 621078. {Epub feb 21, 2011. doi:10.1155/2011/621078}. [PMID 21490781/PMC 3065882]
 138. Gardner EM, McLees MP, Steiner JF, **del Rio C**, Burman WJ. The Spectrum of Engagement in HIV Care and its Relevance to “Test and Treat” Strategies for Prevention of HIV Infection. *Clin Infect Dis* 2011; 52 (6): 793-800. [PMID 21367734/PMC 3106261]. {Article selected for reprint as part of “2010 *Clinical Issues in HIV Medicine*”, published by the Infectious Diseases Society of America} -Article was published with an accompanying editorial: Lange JMA. “Test and Treat”: Is It Enough? *Clin Infect Dis* 2011 (52): 801-2.
 139. Priddy FH, Wakasiaka S, Hoang TD, Smith JD, Farah B, **del Rio C**, Ndinya-Achola J. Anal sex, vaginal practices and HIV incidence in female commercial sex workers in urban Kenya: Implications for development of intravaginal HIV prevention methods. *AIDS Res Human Retroviruses* 2011; 27(10): 1067-72. {Epub ahead of print Mar 15} [PMID 21406032]
 140. Rebolledo-Esteinou P, Kourbatova E, Rothenberg, R, **del Rio C**. Factors Associated with Utilization of HAART amongst hard-to-reach HIV-infected individuals in Atlanta, GA. *J AIDS and HIV Research* 2011; 3(3): 63-70 [PMID 21866279/PMC 3159491].
 141. Frew PM, Hixon B, **del Rio C**, Esteves-Jaramillo A, Omer S. Acceptance of pandemic 2009 influenza A (H1N1) vaccine in a minority population: determinants and potential points of intervention. *Pediatrics* 2011; May; 127 Suppl 1:S113-9. {Epub 2011, Apr 18} [PMID 21502254].
 142. Dionne-Odom J, Tambe P, Yee E, Weinstock H, **del Rio C**. Antimicrobial Resistant Gonorrhea in Atlanta: 1988 – 2006. *Sex Trans Dis* 2011; 38 (8): 780 - 782 {Epub ahead of print March 18; doi: 10.1097/OLQ.0b013e318214e306} [PMID 21844728/PMC 3156986/NIHMS 280105].
 143. Wheatley MA, Copeland B, Shah B, Heilpern K, **del Rio C**, Houry D. Efficacy of Emergency Department Based HIV Screening Program in the Deep South. *J Urban Health* 2011; 88(6): 1015-1019. [PMID 21630105/PMC 3232419].
 144. Hong NT, Wolfe MI, Dat TT, McFarland DA, Kamb ML, Thang NT, Thai HN, **del Rio C**. Utilization of HIV Voluntary Counseling and Testing in Vietnam: An Evaluation

- of Five Years of Routine Program Data for National Response. *AIDS Education and Prevention*, 2011 June;23(3 Suppl):30-48. [PMID 21689035]
145. Frew PM, Archibald M, Hixson B, **del Rio C**. Socioecological influences on community involvement in HIV vaccine research. *Vaccine* 2011; 29 (36): 6136 - 43 [PMID 21722689/PMC 3170874/NIHMS 314370].
 146. **del Rio C**, Hall G, Hook EW, Whittington W, Kirkcaldy R, Papp JR, Weinstock H, Murray EL. Cephalosporin Susceptibility Among *Neisseria gonorrhoeae* isolates – United States, 2000 – 2010. *MMWR* 2011; 60(26): 873 – 977. [PMID 21734634]
 147. Kandelaki G, Butsashvili M, Geleishvili M, Avaliani N, Macharashvili N, Topuridze M, **del Rio C**, Blumberg H, Tsertsvadze T. Nosocomial Infections in Tbilisi, Georgia: A retrospective study of microbiological data from 4 major tertiary hospitals. *Infect Control Hosp Epidemiol* 2011; 32 (9): 933- 4. [PMID 21828982].
 148. Talati N, Gonzalez-Diaz E, Mutemba C, Wendt J, Kilembe W, Mwananyanda L, Chomba E, Allen S, **del Rio C**, Blumberg H. Diagnosis of Latent Tuberculosis Infection among HIV discordant partners using interferon Gamma Releasing Assays. *BMC Infectious* 2011 Sept 30, 11:264 (doi:10.1186/1471-2334-11-264). [PMID 21962029/PMC 3198954].
 149. Steinau M, Reddy D, Sumbry A, Reznik D, Gunthel CJ, **del Rio C**, Lennox JL, Unger ER, Nguyen ML. Oral Sampling and human papillomavirus genotyping in HIV-infected patients. *J Oral Pathol Med* 2012; 41(4): 288 – 91 [PMID 22082117]
 150. Hogan C, DeGruttola V, Sun X, Fiscus SA, **del Rio C**, Bradley Hare C, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Frazier T, Daar ES, Little S. The Setpoint Study (ACTG A5217) – Effect of Immediate versus Deferred Antiretroviral Therapy on Virologic Setpoint in Recently HIV-1 Infected Individuals. *J Infect Dis* 2012; (1): 87 – 96 [PMID 22180621/PMC 3242744]
 151. Doshi RK, Vogenthaler N, Lewis S, Rodriguez A, Metsch L, **del Rio C**. Correlates of antiretroviral utilization among hospitalized HIV-infected crack cocaine users. *AIDS Res Hum Retroviruses* 2012; 28 (9): 1007 – 14. [PMID 22214200/PMC 3423644]
 152. Bonney LE, Cooper HL, Caliendo AM, **del Rio C**. Hunter-Jones J, Swan DF, Rothenberg R, Druss B. Access to Health Services and Sexually Transmitted Infections in a Cohort of Relocating African American Public Housing Residents: An Association Between Travel Time and Infection. *Sex Transm Dis* 2012 Feb; 39(2): 116 – 121 [PMID 22249300]
 153. Copeland BL, Shah B, Wheatley M, Heilpern K, **del Rio C**, Houry D. Diagnosing HIV in Men Who Have Sex with Men: An Emergency Department’s Experience. *AIDS Patient Care and STD* 2012; 26 (4): 202 – 7. [PMID 22356726/PMC 3317392]
 154. Ofotokun I, Sheth AN, Sanford SE, Easley KA, Shenvi N, White K, Eaton ME, **del Rio C**, Lennox JL. A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: the KITE Study. *AIDS Res Human Retroviruses* 2012; 28 (10): 1196 – 206 [PMID 22364141/ PMC3448110].
 155. Kalokhe A, Paranjape A, Bell CE, Cardenas GA, Kuper T, Metsch LR, **del Rio C**. Intimate Partner Violence among HIV-infected crack cocaine users. *AIDS Patient Care and STDs* 2012; 25(4): 234 – 40. [PMID 22364209/PMC 3317393]
 156. Leeds IL, Magee MJ, Kurbatova EV, **del Rio C**, Blumberg HB, Leonard MK, Kraft CS.

- Site of extrapulmonary tuberculosis is associated with HIV infection. *Clin Infect Dis* 2012; 55(1): 75 – 81 [PMID 22423123/PMC 3493181].
157. Frew PM, Painter JE, Hixson B, Kulb C, Moore K, **del Rio C**, Esteves-Jaramillo A, Omer SB. Factors mediating seasonal and influenza A (H1N1) vaccine acceptance among ethnically diverse populations in the urban south. *Vaccine* 2012; 30 (28): 4200 – 8. [PMID 22537991/PMC 35222428]
 158. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, **del Rio C**, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN, for the Step/HVTN 504 study team. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of a recombinant adenovirus HIV vaccine (Step study). *J Infect Dis* 2012; 206 (2): 258 – 66. [PMID 22561365/PMC 3490694]
 159. Goldstein E, Kirkcaldy RD, Reshef D, Berman S, Weinstock H, Sabeti P, **del Rio C**, Hall G, Hook EW, Lipsitch M. Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and other Antimicrobial Drugs in *Neisseria gonorrhoeae*, United States. *Emerg Infect Dis* 2012; 18(8): 1290 – 7. [PMID 22840274/PMC 3414012]
 160. **del Rio C**, Hall G, Holmes K, Soge O, Hook EW, et al. Update to CDC’s *Sexually Transmitted Diseases Treatment Guideline, 2010*: Oral Cephalosporins no Longer a Recommended Treatment for Gonococcal Infections. *MMWR* 2012; 61(31): 590 – 594. [PMID 22874837] (also published in *JAMA* 2012; 308(18): 1850 – 1853)
 161. Kelley CF, Rosenberg ES, O’Hara BM, Sanchez T, **del Rio C**, Sullivan PS. Prevalence of Urethral *Trichomonas vaginalis* in Black and White Men Who Have Sex with Men. *Sex Transm Dis* 2012; 39(9): 739. [PMID 22902674/PMC 3665349]
 162. Edupuganti S, Eidex R, Keyserling H, Orenstein W, **del Rio C**, Akondy R, Lanciotti R, Pan Y, Querec T, Lipman H, Barrett A, Ahmed R, Teuwen D, Cetron M, Mulligan M. A Randomized, double-blind, controlled trial of the 17D Yellow fever virus vaccine in combination with immune globulin or placebo: comparative viremia and immunogenicity. *Am J Trop Med & Hyg* 2013; 88 (1): 172 – 7. [PMID 23208880/PMC 3541731]
 163. Kelley CF, Rosenberg ES, O’Hara BM, Frew PM, Sanchez T, Peterson JL, **del Rio C**, Sullivan PS. Measuring Population Transmission Risk for HIV: An Alternative Metric of Exposure in Men Who Have Sex with Men (MSM) in the US. *PLoS One* 2012; 7 (12): e53284. Doi: 10.1371/journal.pone.0053284. [PMID 23285274/PMC 3532405].
 164. Hodder SL, Justman J, Hughes J, Wang J, Haley D, Adimora AA, **del Rio C**, Golin CE, Kou I, Rompalo A, Soto-Torres L, Mannheimer SB, Johnson-Lewis L, Eshleman SH, El-Sadr W for the HIV Prevention Trials Network 064 ; the Women’s HIV SeroIncidence Study Team. HIV Acquisition Among Women from Selected Areas of the United States: A Cohort Study. *Ann Intern Med* 2013; 158 (1): 10 – 18. [PMID 23277896]
 165. Kirkcaldy RD, Zaidi A, Hook EW, Holmes KH, Soge O, **del Rio C**, Hall G, Papp J, Bolan G, Weinstock HS. *Neisseria gonorrhoeae* Antimicrobial Resistance among Men who Have Sex with Men and Men who have Sex with Women, The Gonococcal Isolate Surveillance Project, 2005 – 2010. *Ann Intern Med* 2013; 158: 321 – 328 [PMID 2346005]

166. Dionne-Odom J, Karita E, Kilembe W, Henderson F, Vwalika B, Bayingana R, Li Zhigang, Mulenga J, Chomba E, **del Rio C**, Khu NH, Tichacek A, Allen S. Syphilis Treatment Response among HIV Discordant Couples in Zambia and Rwanda. *Clin Infect Dis* 2013; 56(23): 1829 – 37. [PMID 23487377/PMC 3658364]
167. Acosta AM, Bonney LE, Fost M, Green VL, del Rio C. HPV Knowledge among a Marginalized Population [Letter]. *Prev Chronic Dis* 2013 Mar; 10:E44. doi: 10.5888/pcd10.130088. [PMID 23537518].
168. Martin D, Dbouk RH, Deleon-Carnes M, **del Rio C**, Guarner J. *Haemophilus influenzae* acute endometritis with bacteremia: case report and literature review. *Diagn Microbiol Infect Dis* 2013 Jun; 76(2): 235 – 6. [PMID 23537790]
169. Guarner, J, Armstrong WS, Satola SW, Mehta AK, Jerris R, Hilinski J, Burd, EM, Kraft CS, **del Rio C**. Development, Implementation, and Evaluation of a 4th year Medical School Elective Course in Clinical Microbiology Using Case-Based Vignettes. *J Med Microbiol* 2013 Jul; 62(Pt 7): 1098 - 110 [PMID 23579393].
170. Guarner J, Burd EM, Williams TC, Jerris R, **del Rio C**. Unusual empyema *Pseudozyma aphidis*. *J Clin Microbiol* 2013; 51(7): 2017 [PMID 23785070/PMC 3697655] & Answer to July 2013 Photo Quiz. *J Clin Microbiol* 2013; 51(7): 2473 [PMID 23785071/PMC 3697724].
171. Koblin BA, Mayer KH, Esheman SH, Wang L, Mannheimer S, **del Rio C**, Shaptaw S, Magnus M, Buchbinder S, Wiltion L, Lui TY, Cummings V, Piwowar-Manning E, Diels SD, Griffith S, Elharrar V, Wheeler D for the HPTN 061 Protocol Team. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV Prevention Trials Network (HPTN) 061. *PLoS ONE* 2013 Jul 26; 8(7): e70413. doi:10.1371/journal.pone.0070413. [PMID 23922989/PMC 3724810]
172. Adimora AA, Hughes JP, Wang J, Haley DF, Golan CE, Magus M, Rompalo A, Justman J, **del Rio C**, El-Sadr W, Mannheimer S, Soto-Torres L, Hodder S. for the HPTN 064 Protocol Team. Characteristics of Multiple and Concurrent Partnerships among Women at High Risk for HIV Infection. *JAIDS* 2014; 65(1): 99 – 106 {Epub ahead of print Sept 4, 2013} [PMID 24056163; PMC 4172374]
173. Hussen SA, Stephenson R, **del Rio C**, Wilton L, Wallace J, Wheeler D, for the HPTN 061 Protocol Team. HIV Testing Patterns among Black Men who have Sex with Men: A Qualitative Typology. *PLoS One* 2013, Sept 19; 8(9): e75382. Doi:10.1371/journal.pone.0075382. [PMID 24069408/PMC 3777907]
174. Marzinke MA, Clarke W, Wang L, Cummings V, Liu T-Y, Piwowar-Manning E, Breaud A, Griffith S, Buchbinder S, Shoptaw S, **del Rio C**, Magnus M, Mannheimer S, Fields SD, Mayer KH, Wheeler DP, Koblin BA, Eshleman SH, and Fogel JM. Non-disclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly-diagnosed and previously-diagnosed HIV infection. *Clin Infect Dis*. 2014; 58(1) 117 - 120. {Epub ahead of print Oct 2, 2013} [PMID 24092804/PMC 3864502].
175. DeMoss M, Bonney L, Grant J, Klein R, **del Rio C**, Backer JC. Perspectives of Middle-Aged African American Women in the Deep South on Antiretroviral Therapy Adherence. *AIDS Care* 2013, Oct 8 {Epub ahead of print} [PMID 24176032].
176. Chkhartishvili N, Kempker RR, Dvani N, Abashidze L, Sharavdze L, Gabunia P, Blumberg H, **del Rio C**. Tsersvadze T. Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the

- country of Georgia. *BMC Infect Dis* 2013; Nov 1; 13(1): 513 {Epub ahead of print} [PMID 24176032/PMC 3817813].
177. Marconi VC, Wu B, Hampton J, Ordonez CE, Johnson BA, Singh D, John S, Gordon M, Hare A, Murphy R, Nachega J, Kuritzkes DR, **del Rio C**, Sunpath H and South Africa Resistance Cohort Study Team. Early Warning Indicators for First-line Failure Independent of Adherence Measures in a South African Urban Clinic. *AIDS Patient Care STDS* 2013 Dec; 27(12): 657 – 68. [PMID 24320011/PMC 3868291]
178. Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, Mcgee MJ, **del Rio C**, Blumberg HM. Hepatitis C Virus co-infection increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity among Patients with Pulmonary Tuberculosis. *PLoS ONE* 2013; 8(12): e83892. doi: 10.1371/journal.pone.0083892. [PMID 24367617/PMC 3817813]
179. Imai K, Sutton MY, Mdofo R, **del Rio C**. HIV and Menopause: A Systematic Review of the Effects of HIV Infection on Age at Menopause and the Effects of Menopause on the Response to Antiretroviral Therapy. *Obstet Gynecol Int.* 2013; 2013: 340309. doi: 10.1155/2013/340309. [PMID 24454386/PMC 3880754]
180. Chkhartishvili N, Sharvadze L, Chokoshvili O, Bolokadze N, Rukhadze N, Kempker R, DeHovitz J, **del Rio C**, Tsertsvadze T. Mortality and causes of death among HIV infected individuals in the country of Georgia: 1989 – 2012. *AIDS Res Hum Retroviruses* 2014 Jun; 30(6): 560 – 6. {epub ahead of print Jan 28} [PMID 24472093/PMC 4046195]
181. Mayer KM, Wang L, Koblin S, Mennheimer S, Magus M, **del Rio C**, Buchbinder S, Wilton L, Cummings V, Watson C, Piwowar-Manning E, Gaydos C, Eshleman SH, Clarke W, Liu T-Y, Griffith S, Wheeler S for the HPTN 061 Team. Concomitant Socioeconomic, Behavioral, and Biological Factors Associated with the disproportionate HIV infection burden among Black Men who have Sex with Men in 6 US Cities. *PLoS ONE* 2014 Jan 31, 9(1): e87298. Doi:10.1371/journal.pone.0087298. [PMID 24498067/PMC 3909083]
182. Hussen SA, Tsegaye M, Argaw MG, Andes K, Gilliard D, **del Rio C**. Spirituality, Social Capital and Service: Factors Promoting Resilience among Expert Patients living with HIV in Ethiopia. *Glob Public Health* 2014 Feb 13 {Epub ahead of print} [PMID 24520996]
183. Winskell K, Evans D, Stephenson R, **del Rio C**, Curran JW. Incorporating Global Health Competencies into the Public Health Curriculum. *Publ Health Reports* 2014; 129 (2): 203 – 208. [PMID 24587558]
184. Sullivan PS, Peterson J, Rosenberg ES, Kelley CF, Cooper H, Vaughan A, Salazar LF, Wingood G, DiClemente R, **del Rio C**, Mulligan M, Sanchez TH. Understanding Racial HIV/STI Disparities in Black and White Men Who Have Sex with Men: A Multilevel Approach. *PLoS ONE* 9(3): e90514. doi:10.1371/journal.pone.0090514. [PMID 2460176/PMC 3946498]
185. Rosa-Chuha I, Hootoon TM, Cardenas GA, **del Rio C**, Bonney LE, Pereyra M, Metsch LR. Human Papillomavirus Awareness among HIV-infected drug users in two urban areas. *Int J STD AIDS* 2014; 25(14): 992-996 {Epub ahead of print March 10}. Doi: 10.1177/0956462414527070 [PMID 24616115]
186. White D, Rosenberg ES, Cooper HL, **del Rio C**, Sanchez TH, Salazar LF, Sullivan PS. Racial differences in the validity of self-reported drug use among men who have sex

- with men in Atlanta, GA. *Drugs & Alcohol Dep* 2014; 138: 146 – 53. doi.org/10.1016/j_drugalcdep.2014.02.25 {Epub ahead of print Feb 25, 2014} [PMID 24629628]
187. Piwowar-Manning E, Fogel JM, Leayendeck O, Wolf S, Cummings V, Merzinke MA, Clarke W, Breaud A, Wendel S, Wang L, Swanson P, Hackett J, Manheimer S, **del Rio C**, Kuo I, Harawa NT, Koblin BA, Moore R, Blakson JN, Echleman SH. Failure to Identify HIV-Infected Individuals in a Clinical Trial Using Single HIV Rapid Test for Screening. *HIV Clin Trials* 2014; 15(2): 62 – 68. [PMID 24710920/PMC 4167641]
 188. Chkhartishvili N, Rukhadze N, Svanidze M, Sharadze L, DeHovitz JA, Tsertsvadze T, McNutt LA, **del Rio C**. Evaluation of multiple measures of antiretroviral adherence in the Eastern European country of Georgia. *J Int AIDS Soc* 2014; Apr 9; 17 (1): 1885. doi: 10.7448/IAS.17.18885.eCollection 2014. [PMID 24721464/PMC 3983475]
 189. Peterson JL, Bakeman R, Sullivan P, Millett GA, Rosenberg E, Salazar L, DiClemente RJ, Cooper H, Kelley CF, Mulligan MJ, Frew P, **del Rio C**, Social Discrimination and Resiliency are not associated with Differences in Prevalent HIV Infection in Black and White Men who had Sex with Men. *J Acquir Immune Defic Syndr* 2014; 66(5): 538 – 43. {Epub ahead of print May 29} [PMID 24820109].
 190. Hussen SA, Andes K, Gilliard D, Chakraborty R, **del Rio C**, Malebranche DJ. Transition to Adulthood and Antiretroviral Adherence Among HIV-Positive Young Black Men Who Have Sex with Men. *Am J Public Health* 2014 {Epub ahead of print June 12} [PMID 24922167]
 191. Chkhartishvili N, Sharavdze L, Chokoshvili O, DeHovitz J, **del Rio C**, Tsertsvadze T. The Cascade of Care in the Eastern European Country of Georgia. *HIV Med* 2015; 16(1): 62 - 66. doi: 10.1111/hiv.12172. {Epub ahead of print June 12, 2014} [PMID 21787384/PMC 3154141].
 192. Hare AQ, Ordonez CE, Johnson BA, **del Rio C**, Kearns RA, Wu B, Hampton J, Wu P, Sunpath H, Marconi VC. Gender-Specific Risk Factors for Virologic Failure in KwaZulu-Natal: Automobile Ownership and Financial Insecurity. *AIDS Behav* 2014; 18(11): 2219-2229 {Epub ahead of print July 19} PPMID 25037488]
 193. Marrazzo JM, **del Rio C**, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson CA. HIV Prevention in Clinical Care Settings: 2014 Recommendations of the International Antiviral Society-USA Panel. *JAMA* 2014; 312(4): 390 – 409. [PMID 25038358]
 194. Hernandez-Romieu AC, Sullivan PS, Sanchez TH, Kelley CF, Peterson JL, **del Rio C**, Salazar LF, Frew PM, Rosenberg ES. The comparability of men who have sex with men recruited from venue-time-space sampling and Facebook: a cohort study. *JMIR Res Protoc* 2014 July 17; 3(3):e37.doi:10.2195/resprot3342. [PMID 25048694]
 195. Sanchez TH, Kelley CF, Rosenberg E, Luisi N, O'Hara B, Lambert R, Coleman R, Frew PM, Salazar LF, Tao S, Clarke W, **del Rio C**, Sullivan PS. Lack of Awareness of HIV Infection: Problems and Solutions with Self-reported HIV Serostatus of Men Who Have Sex with Men. *Open Forum Infectious Diseases* 2014; doi: 10.1093/ofid/ofu084
 196. Chen I, Cummings V, Fogel JM, Marzinke MA, Clarke W, Connor MB, Griffith S, Buchbinder S, Shaptaw S, **del Rio C**, Magnus M, Mannheimer S, Wheeler DP,

- Mayer KH, Koblin BA, Eshleman SH, . Low-level Viremia Early in HIV Infection. *J Acquir Immune Defic Syndr* 2014; 67(4): 405 – 8 {Epub ahead of print Aug 21} [PMID 25140905; PMC 4213245]
197. Cooper HLF, Linton S, Haley DF, Kelley ME, Dauria EF, Karnes CC, Ross Z, Hunter-Jones J, Renneker KK, **del Rio C**, Adimora A, Wingood GM, Rothenberg RR, Bonney LE. Changes in Exposure to Neighborhood Characteristics Are Associated with Sexual Network Characteristics in a Cohort of Adults Relocating from Public Housing. *AIDS and Behavior* 2014 {Epub Aug 24} [PMID 25150728]
 198. Mannheimer SB, Wang L, Wilton L, Tieu HV, **del Rio C**, Buchbinder S, Fields S, Glick S, Conor MB, Cummings V, Eshleman SH, Koblin B, Mayer KH. Infrequent HIV Testing and Late HIV Diagnosis Are Common Among A Cohort of Black Men who have Sex with Men (BMSM) in Six US Cities. *J Acquir Immune Defic Syndr* 2014; 67(4): 438-45 {Epub ahead of print Sept 5} [PMID 25197830]
 199. Cooper HLF, Haley DF, Linton S, Hunter-Jones J, Martin M, Kelley ME, Karnes CC, Ross Z, Adimora AA, **del Rio C**, Rothenberg R., Wingood GM, Bonney LE. Impact of Public Housing Relocations: Are changes in neighborhood conditions related to STIs among relocaters? *Sex Transm Dis* 2014 Oct;41(10):573-9. doi: 10.1097/OLQ.000000000000172. [PMID 25211249]
 200. Lofgren SM, Friedman R, Ghermay R, George M, Pittman JR, Shahane A, Zeimer D, **del Rio C**, Marconi VC. Integrating Early Palliative Care for patients with HIV: Provider and patient perceptions of symptoms and need for services. *Am J Hosp Palliat Care* 2014 Sept 12; doi: 10.1177/1049909114550391. [PMID 25216735]
 201. Okafor N, Rosenberg ES, Luisi N, Sanchez T, **del Rio C**, Sullivan PS, Kelley, CF. Disparities in herpes simplex virus type 2 infection between Black and White Man who have Sex with Men in Atlanta, GA. *Int J STD AIDS* 2014; Sept 22. Pii: 0956462414552814 {Epub ahead of print} [PMID 25246424].
 202. Guarner, J, Burd EM, Kraft CS, Armstrong WS, Lennorr K, Spicer JO, Martin D, **del Rio C**. Evaluation of an online program to teach microbiology to internal medicine residents. *J Clin Microbiol* 2015; 53(1): 278-81. doi: 10.1128/JCM.02696-14. {Epub ahead of print Nov 12} [PMID 2539364]
 203. Ali, MK, McKeever K, Gregg EW, **del Rio C**. A Cascade of Care for Diabetes in the United States: Visualizing the Gaps. *Ann Intern Med* 2014; 161: 681-689. doi: 10.7326/M14-0019 [PMID [25402511](#)]
 204. Kirkcaldy RD, Soge O, Papp JR, Hook EW, **del Rio C**, Kublin G, Weinstock HS. Neisseria gonorrhoeae azithromycin susceptibility in the United States, the Gonococcal Isolate Surveillance Project: 2005 – 2013. *Antimicrob Agents Chemother* 2015; 59(2): 998 – 1003. Doi: 10.1128/AAC.04337-14. {Epub 2014 Dec 1} [PMID 25451056]
 205. Rosenberg ES, Millett GA, Sullivan PS, **del Rio C**, Curran JW. Understanding the HIV disparities between Black and White men who have sex with men in the USA using the HIV care continuum: a modelling study. *Lancet HIV* 2014; 1(3):e112-e118 {Epub ahead of print Nov 18} [PMID 25530987/PMC 4269168]
 206. Kenya S, Chida N, Cardenas G, Pereyra M, **del Rio C**, Rodriguez A, Metsch L. Case Management: Steadfast Resource for Addressing Linkage to Care and Prevention with Hospitalized HIV-infected Crack Users. *J HIV AIDS Soc Serv* 2014; 13(4): 325 – 26. [PMID 25635176; PMC 4307800]

207. Chow JY, Alsan M, Armstrong WS, **del Rio C**, Marconi VC. Risk factors for AIDS-defining illnesses among a population of poorly adherent people living with HIV/AIDS in Atlanta, Georgia. *AIDS Care* 2015; Feb 9: 1 – 5 {Epub ahead of print} [PMID 25660100].
208. Guarner J, Amukele T, Mehari M, Gemechu T, Woldeamanuel Y, Winkler AM, Wilson ML, **del Rio C**. Building Capacity in Laboratory Medicine in Africa by Increasing Physician Involvement: A Laboratory Medicine Course for Clinicians. *Am J Clin Pathol* 2015; 143(3): 405 -411. [PMID 25696799].
209. Leon JS, Winskell K, McFarland DA, **del Rio C**. A case-based, problem-based learning approach to prepare master of public health students for the complexities of global health. *Am J Public Health* 2015 Mar ; 105 (Suppl 1): S92 -6. [PMID 25706029]
210. Weissman HM, Biousse V, Schechter MC, **del Rio C**, Yeh S. Bilateral central retinal artery occlusion associated with herpes simplex virus-associated acute retinal artery necrosis and meningitis: case report and literature review. *Ophthalmic Surg Lassers Imaging Retina* 2015; 46(2): 279 – 83. [PMID 25707059]
211. Kelley C, Vaughan A, Luisi N, Sanchez TH, Salazar LF, Frew P, Cooper H, DiClemente R, **del Rio C**, Sullivan P, Rosenberg E. The effect of high rates of bacterial sexually transmitted infections on HIV incidence in a cohort of black and white men who have sex with men in Atlanta, GA. *AIDS Res Hum Retroviruses* 2015; Jun; 31(6): 587 – 92. doi: 10.1089/AID.2015.0013. [PMID 25719950]
212. Sanchez T, Kelley CF, Rosenberg E, Luisi N, O'Hara B, Lambert R, Coleman R, Frew P, Salazar LF, Tao S, Clarke W, **del Rio C**, Sullivan PS. Lack of Awareness of Human Immunodeficiency Virus (HIV) Infection: Problems and Solutions with Self-reported HIV Serostatus of Men who have Sex with Men. *Open Forum Infect Dis* 2014; Sept 13; 1(2):ofu084. doi: 10.1093/ofid/ofu084. [PMID 25734150; PMC 4281805]
213. Ezewudo MN, Joseph SJ, Castillo-Ramirez S, Dean D, **del Rio C**, Didelot X, Dillon JA, Delden RF, Shafer WM, Turingan RS, Unemo M, Read TD. Population structure of *Neisseria gonorrhoeae* based on whole genome data and its relationship with antibiotics resistance. *Peer J* 2015 Mar 5; 3:e806. doi: 10.7717/peerj.806. eCollection 2015. [PMID 25780762; PMC 4358642]
214. Kalokhe AS, Potdar RR, Stephenson R, Dunkle KL, Paranjape A, **del Rio C**, Sahay S. How Well Does the World Health Organization Definition of Domestic Violence Work in India? *PLoS One* 2015; Mar 26; 10(3):e0120909. doi: 10.1371/journal.pone.0120909. [PMID 25811374; PMC 4374684].
215. Chen I, Connor MB, Clarke W, Marzinke MA, Cummings V, Breaud A, Fogel JM, Laeyendecker O, Fields SD, Donnell D, Griffith S, Scott HM, Schoptaw S, **del Rio C**, Magus M, Mannheimer S, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH. Antiretroviral drug use and HIV drug resistance among HIV-infected Black men who have sex with men: HIV Prevention Trials Network 061. *J Acquir Immune Defic Syndr* 2015 Aug 1;69(4): 446 – 53. doi: 10.1097/QAI.0000000000000633. [PMID 25861015]
216. Vaughan AS, Kelley CF, Luisi N, **del Rio C**, Sullivan PS, Rosenberg ES. An application of propensity score weighting to quantify the casual effect of rectal sexually transmitted infections on incident HIV among men who have sex with men. *BMC Med Res Methodol* 2015 Mar 21; 15(1):25. doi: 10.1186/s12874-015-0017-y.

- [PMID 25888416]
217. Sullivan PS, Rosenberg ES, Travis TH, Kelley CF, Luisi N, Cooper HL, DiClemente RJ, Wingood GM, Frew PM, Salazar LF, **del Rio C**, Mulligan MJ, Peterson JL. Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. *Ann Epidemiol* 2015 Jun; 25(6): 445 - 54. doi: 10.1016/j.annepidem.2015.03.006. {Epub ahead of print} [PMID 25911980]
 218. Piñeirua A, Sierra-Madero J, Cahn P, Guevara Palmero RN, Martinex Buitrago E, Young B, **del Rio C**. The HIV care continuum in Latin America: challenges and opportunities. *Lancet Infect Dis* 2015 Jul; 15(7): 833 – 9. doi: 10.1016/S1473-3099(15)00108-3. [PMID 26122456].
 219. Polgreen PM, Santibanez S, Koonin LM, Rupp ME, Beekmann SE, **del Rio C**. Infectious Disease Physician Assessment of Hospital Preparedness for Ebola Virus Disease. *Open Forum Infect Dis* 2015 Jun 18; 2(3):ofv087. doi: 10.1093/ofid/ofv087. [PMID 26180836/PMCID 4499670].
 220. Kelley CF, Kahle E, Siegler A, Sanchez T, **del Rio C**, Sullivan PS, Rosenberg ES. Applying a PrEP Continuum of Care for Men who Have Sex with Men in Atlanta, GA. *Clin Infect Dis* 2015 Nov 15; 61(10): 1590-7. doi:10.1093/cid/civ664. {Epub 2015 Aug 13} [PMID 26270691].
 221. Caro-Vega Y, **del Rio C**, Dias Lima V, Lopez-Carvantes M, Crabtree-Ramirez B, Bautista-Arredondo S, Colchero MA, Sierra-Madero J. Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model. *PLoS One* 2015 Aug 24; 10(8): e0136534. doi: 10.1371/journal.pone.0136534. [PMID [26302044](#)].
 222. Tukvadze N, Sanikidze E, Kipiani M, Hebbar G, Easley KA, Shenvi N, Kempker RR, Frediani JK, Mirtskhulava V, Alvarez JA, Lomtadze N, Vashakidze L, Hao L, **del Rio C**, Tangpricha V, Blumberg HM, Ziegler TR. High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind, randomized controlled trial. *Am J Clin Nutr* 2015 Nov; 102(5): 1059 – 69. doi: 10.2945/ajcn.115.113886. {Epub Sept 23} [PMID [26399865](#)]
 223. Kirkcaldy RD, Hook EW 3rd, Soge OO, **del Rio C**, Kublin G, Zenilman JM, Papp JR. Trends in Neisseria gonorrhoeae susceptibility to Cephalosporins in the United States, 2006 – 2014. *JAMA* 2015; Nov 3; 314(17): 1869 – 71. doi: 10.1001/jama.2015.10347. [PMID [26529166](#)]
 224. Colasanti J, McDaniel D, Johnson B, **del Rio C**, Sunpath H, Marconi V. Novel Predictors of Poor Retention Following a Down-referral from a Hospital-based ART Program in South Africa. *AIDS Res Hum Retroviruses* 2016 Apr, 32(4):357 – 63. doi: 10.1089/AID.2015.0227. [PMID [26559521](#)].
 225. Colasanti J, Kelly J, Pennisi E, Hu YJ, Root C, Hughes D, **del Rio C**, Armstrong WS. Continuous retention and viral suppression provide further insights into the HIV care continuum compared to the cross-sectional HIV care cascade. *Clin Infect Dis* 2016; 62(5): 648 – 54. doi: 10.1093/cid/civ941. [PMID [26567263](#)].
 226. Goswami ND, Schmitz MM, Sanchez T, Desqupta S, Sullivan P, Cooper H, Rane D, Kelly J, **del Rio C**, Waller LA. Understanding Local Spatial Variation along the Care Continuum: The Potential Impact of Transportation Vulnerability on HIV Linkage to

- Care and Viral Suppression in High-Poverty Areas, Atlanta, Georgia. *J Acquir Immune Def Syndr* 2016 May 1; 72(1): 65 – 72. doi:10.1097/QAI.0000000000000914. [PMID [26630673](#)].
227. Kalokhe AS, Stephenson R, Kelly ME, Dunkle KL, Paranjape A, Solas V, Karve L, **del Rio C**, Sahay S. The Development and Validation of the Indian Family Violence and Control Scale. *Plos One* 2016 Jan 29; 11(1):e0148120. doi: 10.1371/journal.pone.014820. eCollection 2016. [PMID [26824611](#)].
228. Nelson LE, Wilton L, Moineddin R, Zhang N, Siddiqi A, Sa T, Harawa N, Regan R, Dyer TP, Watson CC, Kobin B, **del Rio C**, Buchbinder S, Wheeler DP, Mayer KH; HPTN 061 Study Team. HPTN 061 Study Team. Economic, Legal, and Social Hardships Associated with HIV Risk among Black Men who have Sex with Men in Six US Cities. *J Urban Health* 2016 Feb; 93(1): 170 – 88. doi: 10.1007/s11524-015-0020-y [PMID [26830422](#)].
229. Kalokhe A, **del Rio C**, Dunkle K, Stephenson R, Metheny N, Paranjape A, Sahay S. Domestic violence against women in India: A systematic review of a decade of quantitative studies. *Glob Public Health* 2016 Feb 17: 1 – 16 [PMID [26886155](#)]. doi:10.1080/17441692.2015.1119293.
230. Shah M, Perry A, Risher K, Kapoor S, Grey J, Sharma A, Rosenberg ES, **del Rio C**, Sullivan P, Dowdy DS. Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. *Lancet HIV* 2016 Mar; 3(3):e140-6. [PMID [26939737](#)/PMC4787987] doi: 10.1016/S2352-3018(16)00007-2.
231. Colasanti, J, Goswami ND, Khoubian JJ, Pennisi E, Root C, Ziemer D, Armstrong WS, **del Rio, C**. The perilous road from HIV diagnosis in the hospital to viral suppression in the outpatient clinic. *AIDS Res Hum Retroviruses* 2016 Aug, 32(8): 729 -36 {epub ahead of print March 22} [PMID [27005488](#)]. doi:10.1089/AID.2015.0346.
232. Hernandez-Romieu AC, **del Rio C**, Hernandez-Avila JE, Lopez-Gatell H, Izazola-Licea JA, Uribe-Zuniga P, Hernandez-Avila M. CD4 Counts at Entry to Care in Mexico for Patients under the “Universal Antiviral Treatment Program for the Uninsured Population”, 2007-2014. *PLOS One* 2016 Mar 30; 11(3):e0152444. [PMID [27027505](#)/ PMCID 4814060]. doi: 10.1371/journal.pone.0152444.
233. Frew PM, Archibald M, Schamel J, Saint-Victor D, Fox E, Smith-Bankhead N, Diallo DD, Holstad MM, **del Rio C**. An Integrated Service Delivery Model to Identify Persons Living with HIV and to Provide Linkage to HIV Treatment and Care in Prioritized Neighborhoods: A Geotargeted, Program Outcome Study. *JMIR Public Health Surveill* 2015; Oct 8; 1(2): e16. [PMID [27227134](#)]. doi: 10.2196/publichealth.4675.
234. Bazan JA, Peterson AS, Kirkcaldy RD, et al. Notes from the Field. Increase in *Neisseria meningitidis*–Associated Urethritis Among Men at Two Sentinel Clinics — Columbus, Ohio, and Oakland County, Michigan, 2015. *MMWR Morb Mortal Wkly Rep* 2016; 65:550–552. [PMID [27254649](#)]. doi: 10.15585/mmwr.mm6521a5.
235. Gardner LI, Marks G, Strathdee SA, Loughlin A, **del Rio C**, Kerndt P, Mahoney P, Pitasi MA, Metsch LR. Faster entry into HIV care among HIV-infected drug users who had been in drug-use treatment programs. *Drug and Alcohol Dependence* 2016 Aug 1; 165:15 – 21. [PMID [2729678](#)]. doi:10.1016/drugalcdp.2016.05.018
236. Chen I, Huang W, Connor MB, Frantzell A, Cummings V, Beauchamp GG, Griffith S, Fields SD, Scott HM, Shoptaw S, **del Rio C**, Magus M, Mannheimer S, Tieu HV,

- Wheeler DP, Mayer KH, Koblin BA, Eshelman SH. CXCR4-using HIV variants in a cohort of Black men who have sex with men: HIV Prevention Trials Network 061. *HIV Clin Trials* 2016 Jun 14; 1 – 7 {Epub ahead of print} [PMID [27300696](#)]. doi: 10.1080/15284336.2016.1180771.
237. Unemo M, **del Rio C**, Shafer WM. 2016. Antimicrobial resistance expressed by *Neisseria gonorrhoeae*: a major global public health problem in the 21st century. *Microbiol Spectr* 2016 Jun; 4(3): EI10-0009-2015. [PMID [27337478](#); PMCID 4920088]. doi: 10.1128/microbiolspec.EI10-0009-2015.
238. Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, Jain MK, Rodriguez A, Armstrong WS, Lucas GM, Nijhawan AE, Drainoni ML, Herrera P, Vergara-Rodriguez P, Jacobson JM, Mugavero MJ, Sullivan M, Daar ES, McMahon DK, Lindblad R, VanVeldhuise P, Oden N, Catellon P, Tross S, Haynes LF, Douaihy A, Sorensen JL, Metzger DS, Mander RN, Colfax GN, **del Rio C**. Effect of Patient Navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance abuse: A Randomized Clinical Trial. *JAMA* 2016; 316(2): 156 – 70. doi:10.1001/jama.20168914 [PMID [27404184](#)].
239. Günthard HF, Saag MS, Benson CA, **del Rio C**, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. *JAMA* 2016; 316(2): 191 – 210. doi: 10.1001/jama.2016.8900. [PMID [27404187](#)].
240. Kirkcaldy RD, Harvey A, Papp JR, **del Rio C**, Soge OO, Holmes KK, Hook EW 3rd, Kubin G, Riedel S, Zenilman J, Pettus K, Sanders T, Sharpe S, Torrone E. *Neisseria gonorrhoeae* Antimicrobial Susceptibility Surveillance – The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. *MMWR* 2016; 65(7): 1 – 19. doi: 10.15585/mmwr.ss6508a1. [PMID [27414503](#)].
241. Evans DP, Anderson M, Shahpar C, **del Rio C**, Curran JW. Innovation in Graduate Education for Health Professionals in Humanitarian Emergencies. *Prehosp Disaster Med* 2016; Aug 5: 1 – 7. [PMID [27492749](#)].
242. Frew PM, Parker K, Vo L, Haley D, O’Leary A, Dialo DD, Colin CE, Hou I, Soto-Torres L, Wang J, Adimora AA, Randall LA, **del Rio C**, Hodder S, HIV Prevention Trials Network 064 (HPTN) Study Team. Socioecological factors influencing woman’s HIV risk in the United States: qualitative findings from the woman’s HIV Seroprevalence Study (HPTN 064). *BMC Public Health* 2016 Aug 17; 16 (1): 803; doi:10.1186/s12889-016-3364-7. [PMID [27530401](#); PMCID 4988035].
243. Santibanez S, Polgreen PM, Beekmann SE, Rupp ME, **del Rio C**. Infectious Disease Physicians’ Perceptions About Ebola Preparedness Early in the US Response: A Qualitative Analysis and Lessons for the Future. *Health Secur* 2016 Sept 1 [Epub ahead of print]. doi: 10.1089/hs/2016.0038 [PMID [27584854](#)].
244. Kalokhe AS, Ibegbu CC, Kaur SP, Amara RR, Kelley ME, **del Rio C**, Stephenson R. Intimate Partner Violence is Associated with Increased CD4+ T-cell Activation Among HIV-Negative High-Risk Women. *Pathog Immun* 2016 Spring; 1(1): 193 - 213. [PMID [27668294](#)].
245. Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK,

- Mayer KH, Mugavero MJ, **del Rio C**, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. *AIDS Care* 2016 Dec 2; 1 – 5. doi: 10.1080/09540121.2016.1263721. [PMID [27910703](#)].
246. Chen I, Chau G, Wang J, Clarke W, Marzinke MA, Cummings V, Breaud A, Laeyendecke O, Fields SD, Griffith S, Scott HM, Shoptaw S, **del Rio C**, Magnus M, Mannheimer S, Tieu HV, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH. Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex With Men (HPTN 061). *PLoS One* 2016 Dec 9; 11(12):e0167629. doi: 10.1371/journal.pone.0167629. [PMID [27936098](#)].
247. Chkhartishvili N, Chokoshvili O, Abutidze A, Dvali N, **del Rio C**, Tsertsvadze T. Progress towards achieving the UNAIDS 90-90-90 goals in HIV care: from diagnosis to durable viral suppression in the country of Georgia. *AIDS Res Hum Retroviruses* 2017 Jan 4. doi: 10.1089/AID.2016.0103 [PMID [28051324](#)].
248. Colasanti J, Stahl N, Farber EW, **del Rio C**, Armstrong WS. An Exploratory Study to Assess Individual and Structural Level Barriers Associated with Poor Retention and Re-engagement in Care Among Persons Living with HIV/AIDS. *J Acquir Immune Defic Syndr* 2017 Feb 1; 74 Suppl 2: S113 – S120. doi: 10.1097/QAI.0000000000001242. [PMID [28079721](#)].
249. Mengistu BS, Vins H, Kelly CM, McGee DR, Spicer JO, Derbew M, Bekele A, Matiam DH, **del Rio C**, Blumberg HM, Comeau DL. Student and faculty perceptions of the rapid scale-up of medical students in Ethiopia. *BMC Med Educ* 2017 Jan 13; 17(1):11. doi: 10.1186/s12909-016-0849-0. [PMID [28086953](#)].
250. Goswami ND, Colasanti J, Khoubian JJ, Huang Y, Armstrong WS, **del Rio C**. A Minority of Patients Newly Diagnosed with AIDS are Started on Antiretroviral Therapy at the Time of Diagnosis in a Large Public Hospital in the Southeastern United States. *J Int Assoc Provid AIDS Care* 2017 Mar/Apr; 16(2): 174 – 179. doi: 10.1177/2325957417692679. [PMID [28198210](#)].
251. Levy ME, Phillips G 2nd, Mangus M, Kuo I, Beauchamp G, Emel L, Hucks-Ortiz C, Hamilton RL, Wilton L, Chen I, Mannheimer S, Tieu HV, Scott H, Fields SD, **del Rio C**, Shoptaw S, Mayer K. A Longitudinal Analysis of Treatment Optimism and HIV Acquisition and Transmission Risk Behaviors Among Black Men Who Have Sex with Men in HPTN 061. *AIDS Behav* 2017 Mar 28. Doi: 10.1007/s10461-017-1756-z. [PMID [28352984](#)].
252. Tzeng YL, Bazan JA, Turner AN, Wang X, Retchless AC, Read TD, Toh E, Nelson DE, **del Rio C**, Stephens DS. Emergence of a new *Neisseria meningitidis* clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen. *Proc Natl Acad Sci USA* 2017 Apr 3. pii: 201620971. doi: 10.1073/pnas.1620971114. [PMID [28373547](#)].
253. Chen I, Zhang Y, Cummings V, Cloherty GA, Connor M, Beauchamp G, Griffith S, Rose S, Gallant J, Scott HM, Shoptaw S, **del Rio C**, Kuo I, Mannheimer S, Tieu HV, Hurt CB, Fields SD, Wheeler DP, Mayer K, Koblin BA, Eshelman SH. Analysis of HIV Integrase Residence in Black Men Who Have Sex with Men in the United States. *AIDS Res Hum Retroviruses* 2017 Apr 6. doi: 10.1089/1id.2017.0005. [PMID [28384059](#)].
254. Bazan JA, Turner AN, Kirkcaldy RD, Retchless AC, Kretz CB, Briere E, Tzeng YL, Stephens DC, Maierhofer C, **del Rio C**, Abrams AJ, Trees DL, Ervin M, Licon DB,

- Fields KS, Roberts MW, Dennison A, Wang X. Large Cluster of *Neisseria meningitidis* Urthritis in Columbus, Ohio, 2015. *Clin Infect Dis* 2017; 65(1): 92 - 99. doi: 10.1093/cid/cix215. [PMID [28481980](#)].
255. Alsan M, Beshears J, Armstrong WS, Choi JJ, Marian BC, Nguyen MLT, **del Rio C**, Laibson D, Marconi VC. A commitment contract to achieve cirologic suppression in poorly adherent patients with HIV/AIDS. *AIDS* 2017 May 16. doi: 10.1097/QAD.0000000000001543. [PMID [28514277](#)].
256. Rolle CP, Rosenberg ES, Luisi N, Grey J, Sanchez T, **del Rio C**, Peterson JL, Frew PM, Sullivan PS, Kelley CF. Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia. *Int J STD AIDS* 2017; Aug 28(9): 849-857. doi: 10.1177/0956462416675095. [PMID [28632468](#)].
257. Evans DP, Luffy SM, Parisi S, **del Rio C**. The development of a massive open online course during the 2014-15 Ebola virus disease epidemic. *Ann Epidemiol* 2017; Aug 12. doi:10.1016/j.annepidem.2017.07.137 [PMID [28844550](#)].
258. Hussen SA, Chakraborty R, Knezevic A, Camacho-Gonzalez A, Huang E, Stephenson R. **del Rio C**. Transitioning young adults from paediatric to adult care and the HIV care continuum in Atlanta, Georgia, USA: a retrospective cohort study. *J Int AIDS Soc* 2017 Sept 1; 20(1): 1-9. doi: 10.7448/IAS.20.1.21848 [PMID [28872281](#)].
259. Kirkcaldy RD, Bartoces MG, Soge OO, Riedel S, Kubin G, **del Rio C**, Papp JR, Hook EW 3rd, Hicks LA. Antimicrobial Drug Prescription and *Neisseria gonorrhoeae* Susceptibility, United States, 2005 – 2013. *Emerg Infect Dis* 2017 Oct; 23(10): 1657-1663. doi: 10.3201/eid2310.170488 [PMID [28930001](#)].
260. Howatt Donahoe EL, RochatRW, McFarland D, **del Rio C**. From Albania to Zimbabwe: Surveying 10 years of Summer Field Experiences at the Rollins School of Public Health. *Glob HealthSci Pract* 2017 Sept 28; 5(3): 468 – 475. doi: 10.9745/GHSP-D-16-00262. [PMID [28963176](#)].
- b. Manuscripts published in peer-reviewed journals and acknowledged as a contributor or collaborator
1. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. *Clin Infect Dis*. 2008 Jun 1;46(11):1769-81 [PMID 18433307]
 2. Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, Quirk E; Merck V526-001 Study Group. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.(acknowledged as collaborator) *Clin Vaccine Immunol*. 2009 Sep;16(9):1285-92. Epub 2009 Jul 15. [PMID 19605598/ PMC2745015]
 3. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J*

- Med 2009; 361(23): 2230 – 40 [PMID 19952143/PMC 2800041]
4. Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD, ALLRT team. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. *AIDS* 2010 Jul 31; 24(12): 1867-76. [PMID 20467286/PMC 3018341]
 5. Granich R, Gupta S, Suthar AB, Hoos D, Vitoria M, Simao M, Hankins C, Schwartlander B, Ridzon R, Bazin B, Williams B, Lo YR, McClure C, Montaner J, Hirsch G' ART in Prevention of HIV and TB Research Writing Group. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. *Curr HIV Res* 2011; Sept; 9(6): 446 – 69 [PMID 2199779].
 6. Daar ES, Tierney C, Fischl MA, Sax PE, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1 infection. *Ann Intern Med* 2011; 154(7): 445-56 [PMID 21320923]
 7. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine as part of combination regimens for initial treatment of HIV infection: final results. *J Infect Dis* 2011 Oct 15; 204(8): 1191 - 201[PMID 21917892]
 8. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC, AIDS Clinical Trials Group 5202 Study Team. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/laminudine or tenofovir/emtrocitabine. *Clin Infect Dis* 2014; 58(4): 555 – 63 [PMID 24253247/PMC3905755]
 9. Grand YH, Kirkcaldy RD, Trees D, Dardel J, Harris SR, Goldstein E, Weinstock H, Parkhill J, Hanage WP, Bentley S, Lipsitch M. Genomic epidemiology of *Neisseria gonorrhoeae* with reduced susceptibility to cefixime in the USA: a retrospective observational study. *Lancet Infect Dis* 2014; 14: 220-26.
 10. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC. AIDS Clinical Trials 5202 Study Team. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. *Clin Infect Dis* 2014 Feb; 58 (4): 555 – 63. [PMID 24253247].
 11. Harawa N, Wilton L, Wang L, Mao C, Kuo I, Penniman T, Shoptaw S, Griffith S, Williams JK, Cummings V, Mayer K, Koblin B. HPTN 061. Types of female partners reported by black men who have sex with men and women (MSMW) and association with intercourse frequency, unprotected sex and HIV and STI prevalence. *AIDS Behav* 2014 Aug; 18(8): 1548 – 59. [PMID 24523006].
 12. Ofotokun I, Na LH, Landovitz RJ, Ribaldo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BR, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team. Comparison of the Metabolic Effects of Ritonavir-boosted Darunavir or Atazanavir versus Raltegravir, and the Impact of Rinonavir Plasma Exposure: ACTG5257. *Clin Infect Dis* 2015 Jun 15; 60(12): 1842 – 51. doi: 10.1093/cid/civ193. [PMID 25767256]
 13. Workowski KA, Bolan GA. CDC. Sexually transmitted diseases treatment guidelines,

- 2015; MMWR Recomm Rep. 2015 Jun 5; 64(RR-03): 1- 137. [PMID 26042815].
14. Bayrer C, Bix DL, Bekker LG, Barre-Sinoussi F, Cahn P, Dybul MR, Eholie SP, Kavanagh MM, Katabira ET, Lundgren JD, Mworeko L, Pala M, Puttanakit T, Ryan O, Sidibe M, Montaner JS; Vancouver Consensus Signatories. The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. *Lancet* 2015 Aug 8; 386(9993): 505-7. doi: 10.1016/S0140-6736(15)61458-1. [PMID 26293427]
- c. Review articles and Editorials:
1. **del Río C.** Sarampión: Conceptos actuales sobre un padecimiento antiguo. *Gaceta Med Mex* 1990; 126(2): 121.
 2. Izazola JA, Sánchez HJ, **del Río-Chiriboga C.** El examen serológico para el virus de Inmunodeficiencia Humano (VIH) como parte de los exámenes prenupciales. (The serological exam for the human immunodeficiency virus (HIV) as part of the premarital exams). *Gaceta Med Mex* 1992; 128(3):317-27 [PMID 1302741].
 3. **del Río C,** Uribe-Zuñiga P. Prevención mediante el uso del condón de enfermedades sexualmente transmisibles incluyendo el SIDA. (The prevention of sexually transmitted diseases and HIV/AIDS through the use of condoms). *Salud Públ de México* 1993; 35: 508-17 [PMID 8235898]
 4. **del Río C.** Report from Washington. *AIDS Clinical Care* 1994; 6(3):21-22.
 5. **del Río C.** Linfopenia ideopática de Linfocitos T CD4+ ("SIDA sin VIH"). *Enf Infecc y Microbiol* 1994; 14(2): 108-9.
 6. **del Río C.** New signs on a difficult road. *AIDS Clinical Care* 1994; 6(10):98-112.
 7. Valdespino-Gómez JL, **del Río-Chiriboga C,** García-García ML, del Río-Zolezzi A, Magis-Rodríguez C, Salcedo-Alvarez RA, Loo-Méndez ER. Situación y perspectivas del VIH/SIDA en México. *Enf Infecc y Microbiol* 1995; 15(1): 29-42.
 8. **del Río C.** Second National Conference on Human Retroviruses: Good News, Bad News, and No News. *AIDS Clinical Care* 1995 7(4):30-33 [PMID 11370657].
 9. Valdespino-Gómez JL, García-García L, **del Río-Chiriboga C,** Cruz-Palacios C, Loo-Méndez E, López-Sotelo A. Las enfermedades de transmisión sexual y la epidemia de VIH/SIDA. (Sexually Transmitted diseases and the AIDS epidemic in Mexico). *Salud Públ Méx* 1995; 37 (6): 549-555 [PMID 8599129].
 10. Uribe-Zuñiga P, Hernández-Tepichín G, **del Río-Chiriboga C,** Ortiz V. Prostitución y SIDA en la Ciudad de México. (Prostitution and AIDS in Mexico City). *Salud Públ Méx* 1995; 37 (6): 592-601 [PMID 8599133].
 11. Izazola-Licea JA, Avila-Figueroa C, Gortmaker SL, **del Río C.** Transmisión homosexual del VIH/SIDA en México. (The Homosexual transmission of HIV/AIDS in Mexico). *Salud Públ Méx* 1995; 37 (6): 592-601 [PMID 8599134].
 12. Vallejo-Aguilar OJ, Navarrete-Navarro S, **del Río-Chiriboga C,** Avila-Figueroa C, Santos-Preciado JI. El trabajador de salud y la consejería sobre el VIH y SIDA. (The healthcare workers and counseling about HIV/AIDS). *Salud Públ Méx* 1995; 37 (6): 636-642 [PMID 8599137].
 13. Rico B, Bronfman M, **del Río-Chiriboga C.** Las campañas contra el SIDA en México: ¿Los sonidos del silencio o puente sobre aguas turbulentas? (Campaigns against AIDS in Mexico: The sounds of silence or a bridge over troubled waters?). *Salud Públ Méx* 1995; 37 (6): 643-653 [PMID 8599138].

14. Rico-Galindo B, Uribe-Zúñiga P, Panebianco-Labbe S, **del Río-Chiriboga C**. El SIDA y los derechos humanos. (AIDS and Human Rights). *Salud Públ Méx* 1995; 37 (6): 661-668 [PMID 8599140].
15. del Río-Chiriboga C & del Río-Rodríguez C. Clásicos en Salud Pública. *Salud Públ Méx* 1995; 37 (3):256-263. (Translated into English and published with the title “Yellow-fever in Veracruz” in *Public Health Pap Rep* 1892; 18: 292 – 295; [PMC 2266564])
16. **del Río C**. Tratamientos para el SIDA y Padecimientos Asociados: Costo y Efectividad. *Gaceta Médica de México* 1996; 132 (suppl 1): 77-82.
17. **del Río C**. El tratamiento de la infección por el VIH. Estado actual del arte en 1996 y posibilidades a futuro. *Gaceta Médica de México* 1996; 132 (suppl 1): 125-131.
18. Magis C, Loo EL, **del Río C**. La epidemia de SIDA en México. Análisis global, 1981-1996 (Epidemic of AIDS in Mexico. Global Analysis 1981 – 1996). *Gaceta Médica de México* 1996; 132 (5): 545-550 [PMID 8966625].
19. **del Río C** & Hernández-Tepichín G. Conference Report: Optimism Rises on Combination Therapy and Protease Inhibitor Data. *AIDS Clinical Care* 1996; 8(3):19-23 [PMID 11363408].
20. **del Río C** & Panebianco-Labbé S. AIDS, Human Rights, and NAFTA: Challenges and Opportunities. *Canadian HIV/AIDS Policy & Law Newsletter* 1996; 3(1): 5-6.
21. **del Río C**. Report from Washington Meeting January 22-26. *AIDS Clinical Care* 1997; 9(3):20-23 [PMID 11364122].
22. **del Río C** & Soto-Ramírez LE. Bridging the Gap? *AIDS Clinical Care* 1998; 10(9): 65-72 [PMID 11365808].
23. **del Río C**. Is ethical research feasible in Developed and Developing Countries? *Bioethics* 1998; 12(43): 328-330 [PMID 11657299].
24. Little S & **del Río C**. Time for a change? *AIDS Clinical Care* 1998; 10 (12): 92-98 [PMID 11366070].
25. Izazola-Licea JA, **del Río-Chiriboga C**, Tolbert K. Las Infecciones de transmisión sexual y la pandemia del VIH/SIDA en el ámbito de la salud sexual y reproductiva. *Gaceta Med Mex* 2000; 136 (supl 3): S55-S68.
26. Sobel A, del Río C, Friedland G, O’Rourke M, Rouzioux C, May T. Access to HIV Medical Care. *AIDS Clinical Care* 2000; 12(6): 47-51 [PMID 12212542].
27. **del Río-Chiriboga, C** & Franco-Paredes, C. Bioterrorismo: un Nuevo problema de salud pública. *Salud Publica de Mex* 2001; 43(6):585-588 [PMID 11816235].
28. Bartlett JG & **del Río C**. Antiretroviral rounds. When success is a pain. *AIDS Clinical Care* 2001; 13(8): 74-5 [PMID 11547461].
29. **del Río C**. HIV: it’s beginning to look like a chronic disease. *AIDS Clinical Care* 2001; 13(9): 82-3 [PMID 11547601].
30. Franco-Paredes C, Rebolledo P, Folch E, Hernandez I, **del Río C**. Diagnosis of Diffuse CD8+ Lymphocytosis Syndrome in HIV-Infected Patients. *The AIDS Reader* 2002; 12: 408-413 [PMID 12402804].
31. Franco-Paredes C, **del Río C**, Jurado R. The Clinical Utility of the Urine Gram Stain. *Infect Dis Clin Pract* 2002; 11(9):561-563.
32. Palefsky J & **del Río C**. Is high-grade dysplasia on anal Pap a high-grade problem? *AIDS Clinical Care* 2002; 14(5): 44-5. [PMID 12004877]

33. O'Rourke M, Auerbach J, **del Rio C**, Dooley S, Friedland G, Ridzon R. The place of prevention in HIV clinical care: a roundtable discussion. *AIDS Clinical Care* 2002; 14(6): 49-53 [PMID 12061143].
34. Abdool Karim SS, Currier J, **del Rio C**, Feinberg J, Friedland GH, Sax PE, Zuger A. Report on the XIV International AIDS Conference. *AIDS Clin Care*. 2002 Sep;14(9):77-85 [PMID 12236208]
35. Franco-Paredes C, **del Rio C**, Nava-Frias M, Rangel-Frausto S, Tellez I, Santos-Preciado JI. Enfrentando el bioterrorismo: aspectos epidemiologicos, clinicos y preventivos de la viruela (Confronting bioterrorism: Epidemiologic, Clinical and preventive aspects of smallpox). *Salud Publica de Mexico* 2003; 45 (4):298-309 [PMID 12974047].
36. O'Rourke M, Branson B, **del Rio C**, Larrabee S, Sax PE. Rapid fingerstick testing: a new era in HIV diagnostics. *AIDS Clinical Care* 2003; 15(3): 19-23 [PMID 12685418].
37. **del Rio, C**. Report from the Tenth Retrovirus Conference. Adherence. *AIDS Clin Care*. 2003 Apr;15(4):35 [PMID 12712951]
38. **del Rio C**. Report from the Tenth Retrovirus Conference. Diagnostics. *AIDS Clin Care*. 2003 Apr;15(4):35 [PMID 12712950]
39. **del Rio C**. Report from the Tenth Retrovirus Conference. Acute and recent infection. *AIDS Clin Care*. 2003 Apr;15(4):34-5 [PMID 12712949]
40. **del Rio C**. Report from the Tenth Retrovirus Conference. Postexposure prophylaxis (PEP). *AIDS Clin Care*. 2003 Apr;15(4):35-6 [PMID 12712952]
41. **del Rio C**. New Challenges in HIV Care: Prevention among HIV-infected patients. *Top HIV Med*. 2003 Jul-Aug (4)140-4 [PMID 12876332].
42. Bartlett J, **del Rio C**, DeMaria A Jr., Sepkiwitz KA. Smallpox vaccination and the HIV-infected patient: a roundtable. *AIDS Clinical Care* 2003; 15(7): 61-63 [PMID 12913953].
43. Franco-Paredes C, Tellez I, **del Rio C**. Inverse Relationship between Decreased Infectious Diseases and Increased Inflammatory Disorder Occurrence: The Price to Pay. *Arch Med Research* 2004; 35:258-261 [PMID 15163470].
44. **del Rio C**. Report from the 11th conference on retroviruses and opportunistic infections. HIV in resource-limited countries. *AIDS Clin Care*. 2004 Apr;16(4):34-5. [PMID15124588]
45. **del Rio C**. Report from the 11th conference on retroviruses and opportunistic infections. STI. *AIDS Clin Care*. 2004 Apr;16(4):27-8. [PMID 15124582].
46. **del Rio C**. Report from the 11th conference on retroviruses and opportunistic infections. Acute and recent infection. *AIDS Clin Care*. 2004 Apr;16(4):25-6. [PMID 15124580]
47. **del Rio C**. Report from the 11th conference on retroviruses and opportunistic infections. Epidemiology. *AIDS Clin Care*. 2004 Apr;16(4):25. [PMID 15124579]
48. **del Rio C**. Updated guidelines for the use of rifamycins in HIV/TB-coinfected patients. *AIDS Clinical Care* 2004; 16(10): 85 [PMID 15526395].
49. Franco-Paredes C, Tellez I, **del Rio C**, Santos-Preciado JI. Pandemia de Influenza: posible impacto de la influenza aviaria. *Salud Publ Mex* 2005; 47(2): 1 – 2 [PMID 15889635].
50. Franco-Paredes C, Rodriguez A, **del Rio C**. Lepromatous Leprosy (Images in Infectious diseases). *Infections in Medicine* 2005; 22(5): 229.
51. **del Rio C** & Priddy FH. Outcomes for Patients Receiving Antiretroviral Therapy in the Developing World Appear to be Not Much Different from those in the Developed World (Editorial). *Clin Infect Dis* 2005; 41:225-6. [PMID 15983919]

52. **del Rio C.** Top Stories of 2004. ACTG5095:efavirenz beats AZT+3TC+abacavir. *AIDS Clin Care* 2005 Jan;17(1):4 [PMID 1517367].
53. **del Rio C.** New guidelines for antiretroviral therapy in non-occupational post-exposure prophylaxis. *AIDS Clinical Care* 2005; 17(3): 22 [PMID 15828116].
54. **del Rio C.** Report from the 12th Retrovirus Conference. HIV-associated dementia. *AIDS Clin Care.* 2005 Apr;17(4):41. [PMID 15884151]
55. Albrecht H, **del Rio C.** Report from the 12th Retrovirus Conference. Vaccines, microbicides, and novel prophylactic interventions. *AIDS Clin Care.* 2005 Apr;17(4):42, 44 [PMID 15880874]
56. **del Rio, C.** Report from the 12th Retrovirus Conference. Opportunistic infections. *AIDS Clin Care.* 2005 Apr;17(4):41. [PMID 15880872]
57. **del Rio C,** Friedland GH. Report from the 12th Retrovirus Conference. HIV/AIDS in resource-limited settings. *AIDS Clin Care.* 2005 Apr;17(4):39-40. [PMID 15875314]
58. **del Rio C.** New USPSTF guidelines on HIV screening. *AIDS Clinical Care* 2005; 17(8): 74. [PMID 16193572]
59. **del Rio C.** AIDS: The Second Wave. *Arch Med Res* 2005; 36:682-688.
60. **del Rio C.** Updated Guidelines for occupational postexposure prophylaxis. *AIDS Clinical Care* 2005; 18 (12): 114. [PMID 16388540]
61. Franco-Paredes C, Roupheal N, **del Rio C,** Santos-Preciado JI. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates. *Int J Infect Dis* 2006; 10(2): 93-102. [PMID 16377228]
62. Koenig SP, Kuritzkes DR, Hirsch MS, Leandre F, Mukherjee JS, Farmer PE, **del Rio C.** Monitoring HIV Treatment in Developing Countries. *Br Med J* 2006; 332: 602 – 604. [PMID 16528087/PMC 1397781]
63. **del Rio C.** Report from the 13th Retrovirus Conference: More on False-positive results in rapid HIV testing. *AIDS Clinical Care* 2006; 18(4): 39. [PMID 16718855]
64. **del Rio C.** Report from the 13th Retrovirus Conference: The new ABC's: Antiretrovirals, Barriers and Circumcision. *AIDS Clinical Care* 2006; 18(4): 38 - 9.[PMID 16718884]
65. Buehler JW, Craig AS, **del Rio C,** Koplan JP, Stephens DS, Orenstein WA. Critical issues in responding to pandemic influenza [conference summary]. *Emerg Infect Dis* [serial on the Internet]. 2006 Jul; 12 (7). Available from <http://www.cdc.gov/ncidod/EID/vol12no07/06-0463.htm>
66. **del Rio C.** Current Concepts in Antiretroviral Therapy Failure. *Top HIV Med* 2006; 14(3): 102-106. [PMID 16946454]
67. **del Rio C.** Guideline watch. CDC recommends universal, routine adult HIV screening. *AIDS Clinical Care* 2006 Nov;18(11):1.
68. Franco-Paredes C, Tellez I, **del Rio C.** Rapid HIV Testing: a review of the literature and implications for the clinician. *Current HIV/AIDS Reports* 2006; 3: 159 – 165. [PMID 17049869]
69. Tellez I, Calderon O, Franco-Paredes C, **del Rio C.** West Nile Virus: a reality in Mexico. *Gaceta Med Mex* 2006; 142(6): 493-499.
70. **del Rio C.** Report from the 14th Retrovirus Conference. The HIV/AIDS epidemic in the U.S. *AIDS Clin Care.* 2007 May;19(5):37-8. [PMID 18398986]
71. **del Rio C.** Report from the 14th Retrovirus Conference. The promise of prevention: male circumcision and microbicides. *AIDS Clin Care.* 2007 May;19 (5):41. [PMID 18401877]
72. Tellez I, Franco-Paredes C, Bendix JM, Caliendo A, **del Rio C.** Assessing the Strengths

- and Limitations of Rapid HIV Tests. *Infect Med* 2007; 24: 381-85. [PMID 17201112]
73. Bonney LE & **del Rio C**. Challenges Facing the US HIV/AIDS Medical Care System. *Future HIV Therapy* 2008; 2(2): 1 – 6.
 74. **del Rio C**. Report from the 15th Retrovirus Conference. Continued problems with late diagnosis and new problems with testing scale-up. *AIDS Clinical Care* 2008 Apr; 20(4):26-7 [PMID 19256086].
 75. **del Rio C**. Report from the 15th Retrovirus Conference. More setbacks in HIV Prevention. *AIDS Clinical Care* 2008 Apr; 20(4):25-6 [PMID 19256085].
 76. **del Rio C**. Updated antiretroviral treatment guidelines from DHHS and EACS. *AIDS Clin Care*. 2008 Jan;20(1):7. [PMID 18399008]
 77. **del Rio C**. HIV-1 vaccine might increase infection risk in certain subgroups. *AIDS Clin Care*. 2008 Jan;20(1):5. [PMID 18399007]
 78. **del Rio C**. To stories of 2008. Crash and burn of HIV vaccine candidates. *AIDS Clinical Care* 2009 Jan; 21(1):4 [PMID 19219958].
 79. Whitaker, J, Franco-Paredes C, **del Rio C**, Edupuganti S. Rethinking Typhoid Fever Vaccines: Implications for Travelers and Those Living in Highly Endemic Areas. *J Travel Med* 2009; 16: 49 – 52 [PMID 19192128].
 80. Franco-Paredes C, Hidron A, Tellez I, Lesesne J, **del Rio C**. HIV Infection and Travel: Pretravel Recommendations and Health-Related Risks. *Topics HIV Med* 2009; 17(1): 2 – 11 [PMID 19270343].
 81. Garcia-Calleja JM, **del Rio C**, Souteyand Y. HIV Infection in the Americas: Improving Strategic Information to Improve Response. *JAIDS* 2009; 51 (suppl 1): S1-S3. [PMID 19384095]
 82. Franco-Paredes C, **del Rio C**, Carrasco P, Santos Preciado JI. Respuesta en Mexico al actual brote de influenza A H1N1. *Salud Publ Mex* 2009; 51 (3): 183 – 186 [PMID 19967302].
 83. Tamma PD, Ault KA, **del Rio C**, Steinhoff MC, Halsey NA, Omer SB. Safety of Influenza Vaccination during Pregnancy. *Am J Obst & Gynecol* 2009 Dec; 201 (6): 547 – 52. {E-pub ahead of print Oct 21} [PMID 19850275].
 84. Bonney LE & **del Rio C**. An HIV/AIDS Fellowship Program for Minority Physicians. *J Natl Med Assoc* 2009; 1011: 1297 – 8.[PMID 20070021]
 85. Armstrong WS & **del Rio C**. HIV-associated resources on the internet. *Top HIV Med* 2009; 17(5): 151-62. [PMID 20068262]
 86. **del Rio C**. Report from the 16th Conference on Retroviruses and Opportunistic Infections. First (sort of) positive anti-HIV microbicide trial. *J Watch AIDS Clin Care*. 2009 Apr; 21(4):34. [PMID 19544618]
 87. **del Rio, C**. Report from the 16th Conference on Retroviruses and Opportunistic Infections. Treatment is preventive, but some risk remains. *J Watch AIDS Clin Care*. 2009 Apr; 21(4):32. [PMID 19544616]
 88. **del Rio C**, Sierra-Madero J. Swine-origin influenza A (H1N1) and HIV. The CDC offers guidance for HIV-infected patients potentially exposed to swine flu. *J Watch AIDS Clin Care*. 2009 Jun;21(6):51 [PMID 19544612]
 89. **del Rio C** & Franco-Paredes C. The perennial threat of influenza pandemics. *Arch Med Res* 2009; 40(8): 641-2. [PMID 20304250]
 90. Santos-Preciado J, Franco-Paredes C, Hernandez-Florez I, Tellez I, **del Rio C**, Tapia-Conyer R. What have we learned from the Novel Influenza A (H1N1) Pandemic in 2009

- for Strengthening Pandemic Influenza Preparedness? Arch Med Res 2009; 40: 673-676 [PMID 20304255]
91. **del Rio C** & Hernandez-Avila M. Lessons from Previous Influenza Pandemics and from the Mexican Response to the Current Influenza Pandemic. Arch Med Res 2009; 40: 677-680 [PMID 20304256].
 92. Franco-Paredes C, Hernandez-Ramos I, **del Rio C**, Alexander KT, Tapia-Conyer R, Santos-Preciado JI. H1N1 Influenza Pandemics: Comparing the Events of 2009 in Mexico with those of 1976 and 1918-1919. Arch Med Res 2009; 40: 669-672. [PMID 2030452]
 93. Southwick F, Katona P, Kauffman C, Monroe S, Pirofski LA, **del Rio C**, Gallis H, Dismukes W. IDSA Guidelines for Improving the Teaching of Preclinical Medical Microbiology and Infectious Diseases. Academic Medicine 2010; 85(1): 19 – 22. [PMID 20042815]
 94. **del Rio C**. Report from the 17th Conference on Retrovirus and Opportunistic Infections. Expanding HIV testing and treatment. J. Watch AIDS Clin Care 2010; Apr; 22(4): 29-30. [PMID 20480617]
 95. **del Rio C**. Report from the 17th Conference on Retrovirus and Opportunistic Infections. 2009 H1N1 influenza and HIV infection. J Watch AIDS Clin Care 2010; Apr; 22(4): 32 - 3. [PMID 20480931]
 96. Vogenthaler N & **del Rio C**. Is directly observed therapy worthwhile in the Treatment of HIV infection? J Watch AIDS Clin Care 2010; Jun; 22(6):55. [PMID 20666005]
 97. del Rio C. CD4-cell counts at entry into care: improving but far from ideal. J Watch AIDS Clin Care 2010; Jun; 22(6):52 [PMID 20648722]
 98. **del Rio C** & Guarner J. The 2009 Influenza A (H1N1) Pandemic: what have we learned in the past 6 months. Trans Am Clin Climatol Assoc 2010; 121: 128 - 140. [PMID 20697556/PMC 2917128]
 99. Albarracin D, Rothman AJ, DiClemente R, **del Rio C**. Wanted: A Theoretical Roadmap to Research and Practice Across Individual, Interpersonal and Structural Level of Analysis. AIDS Behav 2010; Sept 8 {E-pub ahead of print}. [PMID 20824321]
 100. Armstrong WS & **del Rio C**. Gender, Race, and Geography: Do They Matter in Primary Human Immunodeficiency Infection? J Infect Dis 2011; 203: 437-438 [PMID [21245158](#)/PMC 3071221]. {Article selected for reprint as part of “2010 Clinical Issues in HIV Medicine”, published by the Infectious Diseases Society of America}
 101. Margoles L, **del Rio C**, Franco-Paredes C. Leprosy: a modern assessment of an ancient neglected disease. Bol Med Hosp Infant Mex 2011; 68(2): 110-116.
 102. **del Rio, C**. Obstacle course: the role of health care providers in helping overcome stigma, denial, and ignorance. Posit Aware 2011 Spring; 23(4): 7 – 9. [PMID 21710874]
 103. **del Rio C**. Latinos and HIV Care in the Southeastern United States: New Challenges Complicating Longstanding Problems. Clin Infect Dis 2011; 53: 488 – 489 [PMID 21844032].
 104. Narayan KM, Ali MK, **del Rio C**, Koplan JP, Curran J. Global Noncommunicable Diseases – Lessons from the HIV-AIDS Experience. N Engl J Med 2011; 365 (10): 876 – 878. [PMID 21899448]
 105. **del Rio C**, Armstrong W. Antiretroviral therapy programmes in resource limited settings. BMJ 2011 Nov 9 343:d6853. doi: 10.1136/bmj.d6853. [PMID [22074712](#)]
 106. Koplan JP, Curran J, Debas H, **del Rio C**, Gostin LO, Keusch GT, Wasserheit JN, In

- support of the US Centers for Disease Control and Prevention. *Lancet* 2012; 379(9826): 1585. [PMID 22541570]
107. **del Rio C**, Mayer, K. A Tale of Two Realities: What are the challenges and the solutions to improving engagement in HIV care? *Clin Infect Dis* 2013 57(8): 1172 – 4. {Epub ahead of print June 23} [PMID [23797287](#)]
 108. Guarner J & **del Rio C**. What educators do not like to deal with. *Am J Clin Pathol* 2014; 141(6): 770 – 1. [PMID [24838318](#)].
 109. Nachega, JB, Uthman OA, **del Rio C**, Mugavero MJ, Rees H, Mills EJ. Addressing the Achilles' Heel in the HIV Care Continuum for the Success of a Test-and-Treat Strategy to Achieve an AIDS-Free Generation. *Clin Infect Dis* 2014; 59 (Suppl 1): S21 – 7. [PMID [24926028](#)]
 110. Armstrong WS, **del Rio C**. Falling through the cracks and dying: missed clinic visits and mortality among HIV-infected patients in care. *Clin Infect Dis* 2014; 59(10): 1480-82 {Epub ahead of print August 4}. [PMID [25091313](#)]
 111. Crabtree-Ramirez B, **del Rio C**, Grinsztejn B, Sierra-Madero J. HIV and Noncommunicable Diseases (NCDs) in Latin America: A Call for an Integrated and Comprehensive Response. *J Acquir Immune Defic Syndr* 2014; 67 (suppl 1): S96 – 8. [PMID [25117966](#)].
 112. **del Rio C**, Mehta AK, Lyon III GM, Guarner J. Ebola Hemorrhagic Fever in 2014: The Tale of an Evolving Epidemic. *Ann Intern Med* 2014; 161(10): 746-8 {Epub Aug 19; doi: 10.7326/M14-1880} [PMID [25133433](#)].
 113. **del Rio C**. HIV prevention: integrating biomedical and behavioral interventions. *Top Antivir Med* 2014; Dec-2015; Jan 22(5): 702 – 6. [PMID [25612180](#)]
 114. Greenberg AE, Purcell DW, Gordon CM, Barasky RJ, **del Rio C**. Addressing the Challenges of the HIV Continuum of Care in High-Prevalence Cities in the United States. *JAIDS* 2015; May 1; 69 (suppl 1): S1 – S7. [PMID [25867773](#)]
 115. **del Rio C**, Guarner J. Ebola: Implications and Perspectives. *Trans Am Clin Climatol Assoc* 2015; 126:93 – 112. [PMID [26330663](#)].
 116. Flannery B, **del Rio C**. Appreciation: Phillip S. Brachman, 1927 – 2016. *Int J Epidemiol* 2016 Jun; 45(3): 602 – 4. doi:10.1093/ije/dyw190. [PMID [27450860](#)].
 117. **del Rio C**. HIV Infection in Hard-to-Reach Populations. *Top Antivir Med* 2016 Jul/Aug; 24 (2): 86 – 89. [PMID [27841977](#)].
 118. Benson CA, Currier JS, **del Rio C**, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding PA. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. *Top Antivir Med* 2017 Dc/Jan; 24 (4): 142 – 151. [PMID [28208122](#)].
 119. Armstrong WS, **del Rio C**. Patient tracking as a tool to improve retention in care, is the juice worth the squeeze? *Clin Infect Dis* 2017 Mar 17. doi: 10.1093/cid/cix196. [PMID [28329039](#)].
 120. Walensky RP, **del Rio C**, Armstrong WS. Charting the Future of Infectious Diseases: Anticipating and Addressing the Supply and Demand Mismatch. *Clin Infect Dis* 2017 Apr 6. doi: 10.1093/cid/cix173. [PMID [28387806](#)].
 121. **del Rio C**. The global HIV epidemic: What the pathologist needs to know. *Semin Diagn Pathol* 2017 May 19. pii: S0740-2570(17)30059-X. doi: 10.1052/j.semmp.2017.05.001. [PMID [28566241](#)].
 122. **del Rio C** & Armstrong WS. Progress Toward Achieving UNAIDS 90-90-90 in Rural

Communities in East Africa. *JAMA* 2017 Jun 6; 317(21): 2172 – 2174. doi: 10.1001/jama.2017.5704. [PMID [28586873](#)].

123. Del Rio, C. From Trained Infectious Diseases Clinician to Global Health Leader, Reflections on the last 30 years. *J Infect Dis* 2017; 216 (suppl 5): S622 – 623. doi: 10.1093/infdis/jix248. [PMID [28938037](#)]

d. Book chapters:

1. Stephens DS, **del Río C**. Gonococcal Diseases. In: Kelly WN (ed.), *Textbook of Internal Medicine*, 1989 (1st. Ed.), pp 1519-1524 & 1991 (2nd. Ed.), pp 1382-1387; JB Lippincott, Philadelphia.
2. McGowan JE Jr, **del Río C**. Other Gram-Negative Bacilli, In: Mandell, Douglas, Bennett (eds.): *Principles and Practice of Infectious Diseases*, 3rd. Ed. 1990. pp 1782-93.
3. Bartley DC, **del Río C**, Shulman JA. Clinical Complications. In: Schlossberg D. *Infectious Mononucleosis*, 2nd Ed. Springer-Verlag Publ. 1989. pp 35-48.
4. Prokesch R, **del Río C**, Shulman JA. Amebiasis. In: Hurst JW. *Medicine for the Practicing Physician*, 3rd Ed. Butterworth-Heinemann 1992. pp 425-28.
5. **del Río C**, Shulman JA. Chronic Fatigue Syndrome. In: Hurst JW. *Medicine for the Practicing Physician*, 3rd Ed. Butterworth-Heinemann 1992. pp 467-69.
6. **del Río C**. Human T cell Lymphotropic virus type 1 infections. In: Hurst JW. *Medicine for the Practicing Physician*, 3rd Ed. Butterworth-Heinemann 1992. pp 479-81.
7. **del Río C**. Enfermedades de Transmisión por Contacto Sexual. In: *Antología de la Sexualidad Humana*. CONAPO 1994. Vol III pp 423-450. (ISBN 970-628-063-4).
8. **del Río C**. Infección por el Virus de Inmunodeficiencia Humana. In: *Antología de la Sexualidad Humana*. CONAPO 1994. Vol III pp 451-491. (ISBN 970-628-063-4).
9. **del Río C**. Parvovirus. In: Uribe M. *Tratado de Medicina Interna*, 2nd De. Editorial Panamericana 1995. pp 1471-1473. (ISBN 986-7157-56-9).
10. **del Río C**. Infección por Citomegalovirus durante el embarazo. In: Uribe M. *Tratado de Medicina Interna*, 2nd De. Editorial Panamericana 1995. pp 1840-1842. (ISBN 986-7157-56-9).
11. **del Río C**, Schwarzmann SW, Hugley CM. Infectious Mononucleosis. In: Hurst JW. *Medicine for the Practicing Physician*, 4th Ed. Appleton & Lange 1996. pp 497-499 (ISBN 0-8385-6317-1).
12. **del Río C** & Shulman JA. Chronic Fatigue Syndrome. In: Hurst JW. *Medicine for the Practicing Physician*, 4th Ed. 1996. pp 500-502 Appleton & Lange (ISBN 0-8385-6317-1).
13. Morgan J & del Río C. Amebiasis. In: Hurst JW. *Medicine for the Practicing Physician*, 4th Ed. Appleton & Lange 1996. pp 457-459 (ISBN 0-8385-6317-1).
14. Gunthel CJ & **del Río C**. Human T-cell Lymphotropic Virus Type I Infections. In: Hurst JW. *Medicine for the Practicing Physician*, 4th Ed. Appleton & Lange 1996. pp 514-517 (ISBN 0-8385-6317-1).
15. **del Río C**. Tuberculosis y SIDA. En: Sifuentes J & Sada E. *Tuberculosis en México*. Interamericana-McGraw-Hill Vol III (4), 1995. pp 795-808 (ISBN-968-25-2471-7).
16. **del Río C**, Granter SR, Duray PH. Lyme Borreliosis. In: Horsburgh CR & Nelson AM: *Pathology of Emerging Infections*. American Society for Microbiology 1997. pp269-283 (ISBN 1-55581-120-5).

17. **del Rio C.** Mujer y SIDA: Conceptos sobre el tema. En: Rico B, Vandale S, Allen B y Liguori AL. Situación de las Mujeres y el VIH/SIDA en América Latina. Instituto Nacional de Salud Pública 1997. Pp: 15-19. (ISBN 968-6502-30-0).
18. Schuklenk U, **del Rio C**, Magis C, Chokevivat V. AIDS in the Developing World. In: Chadwick, Ruth (Ed.) *Encyclopedia of Applied Ethic, Vol 1*. Academic Press 1998, San Diego, Ca. pp: 123-127.
19. Schuklenk U, Chokevivat V, **del Río C**, Gbadegesin S, Magis C. AIDS: ethical issues in the Developing World. In: H. Kuhse & P. Singer (Eds): *A Companion to Bioethics*. Blackwell Publishers Ltd. Oxford 1998, pp. 355-365. (ISBN 0-631-19737-0).
20. **del Rio C** & Meier FA. Yellow fever. In: Nelson AM & Horsburgh CR: *Pathology of Emerging Infections 2*. American Society for Microbiology 1998. pp 13-41 (ISBN 1-55581-140-X).
21. **del Rio C** & Curran JW. Epidemiology of HIV Infection and AIDS. In: Goldman and Bennett: *Cecil Textbook of Medicine*, 21st Ed. 2000, pp 1898-1904. (ISBN 0-7216-7995-1).
22. **del Rio C** & Curran JW. Epidemiology and Prevention of AIDS and HIV Infection. In: Mandell, Bennett & Dolin: *Principles and Practice of Infectious Diseases*, 5th Edition. W.B. Saunders 2000, pp 1340-1368 (ISBN 0-443-07593-X).
23. Steinberg J & **del Rio C**. Other Gram-Negative Bacteria. In: Mandell, Bennett & Dolin: *Principles and Practice of Infectious Diseases*, 5th Edition. W.B. Saunders 2000, pp 2459-2474 (ISBN 0-443-07593-X).
24. **del Rio C** & Cahn P. Antiretroviral Therapy and Treatment of Illnesses Associated with HIV/AIDS: General Considerations and Implications for Latin America and the Caribbean. In: JA Izazola: *AIDS in Latin America and the Caribbean: a multidisciplinary view*. Funsalud/SIDALAC/UNAIDS 1999, pp 85-106 (ISBN 968-5018-17-0).
25. Magis C & **del Rio C**. Epidemiología del VIH y del SIDA en México. In Ponce de Leon S & Rangel S. *SIDA: Aspectos Clínicos y Terapéuticos*. McGraw-Hill Interamericana 2000, pp 1-10 (ISBN 970-10-2527-X)
26. **del Rio C** & Franco-Peredes C. Bioterrorism: A New Public Health Problem. In: Sepulveda J: *Panamerican Health in the 21st Century: Strengthening International Cooperation and Development of Human Capital*. National Institute of Public Health 2002, pp 115 –118 (ISBN 968-6502-59-9).
27. **del Rio C** & Sepulveda J. Infection by HIV/AIDS in Mexico. In: Sepulveda J: *Panamerican Health in the 21st Century: Strengthening International Cooperation and Development of Human Capital*. National Institute of Public Health 2002, pp 97 - 101 (ISBN 968-6502-59-9).
28. **del Rio C** & Curran JW. Epidemiology and Prevention of AIDS and HIV Infection. In: Mandell, Bennett & Dolin: *Principles and Practice of Infectious Diseases*, 6th Edition. Elsevier Inc. 2005; pp 1477-1506 (ISBN 0-443-06643-4).
29. Steinberg J & **del Rio C**. Other Gram-Negative and Gram-Variable Bacilli. In: Mandell, Bennett & Dolin: *Principles and Practice of Infectious Diseases*, 6th Edition. Elsevier Inc. 2005; pp 2751-2768 (ISBN 0-443-06643-4).
30. **del Rio C**. Prevention of Human Immunodeficiency Virus Infection. In Goldman & Ausiello: *Cecil Medicine 23rd Ed*. Elsevier Inc 2008; pp 2567 - 2571 (ISBN 987-1-4160-2805-5)
31. Celentano DD, Bayer C, Davis WW and **del Rio C**. The HIV/AIDS Epidemic of the Americas. In: DD Celentano C Bayer: *Public Health Aspects of HIV/AIDS in Low and*

- Middle Income Countries. Epidemiology, Prevention and Care.* Springer 2008; 525 – 530. (ISBN 978-0-387-72710-3)
32. Dionne-Odom J, Bonney L & **del Río C**. Access to Culturally Competent Care for Patients Living with HIV/AIDS. In: Stone, Ojikutu, Rawlins et al: *HIV/AIDS in Minority Communities*. Springer 2009; 69 – 82. (ISBN 978-0-387-98151-2)
 33. **del Río C** & Curran JW. Epidemiology and Prevention of AIDS and HIV Infection. In: Mandell, Bennett & Dolin: *Principles and Practice of Infectious Diseases*, 7th Edition. Elsevier Inc. 2010; pp 1635 – 1661 (ISBN 978-0-4430-6839-3).
 34. Guarner J & **del Río C**. Pathology, Diagnosis, and Treatment of Anthrax in Humans. In: Bergman NH: *Bacillus anthracis and Anthrax*. Wiley-Blackwell 2011; pp 251 – 267 (ISBN 978-0-470-41011-0)
 35. Doshi RK, **del Río C** & Marconi VC. (2011) Social Determinants of HIV Health Care: A Tale of Two Cities. In: *Understanding HIV/AIDS Management and Care – Pandemic Approaches in the 21st Century*. Fyson Hanania Kasenga (Ed.) (ISBN 978-953-307-603-4; InTech, available at: <http://www.intechopen.com/books/understanding-hiv-aids-management-and-care-pandemic-approaches-in-the-21st-century/social-determinants-of-hiv-health-care-a-tale-of-two-cities>)
 36. **del Río C** & Curran JW. Chapter 121: Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. In: Bennett & Dolin & Blaser: *Principles and Practice of Infectious Diseases*, 8th Edition pp: 1483 – 1502. Elsevier 2015. ISBN-13: 9781455748013
 37. **del Río C** & Cohen MS. Chapter 387: Prevention of Human Immunodeficiency Virus Infection. In: Goldman-Cecil *Medicine* 25th Edition pp: 2285 – 2287. Elsevier-Saunders. 2016. ISBN: 978-1-4557-5017-7.
 38. Franco-Paredes C, Hare A, **del Río C**. Leprosy in Latin America and the Caribbean: Burden of Disease and Approaches to Elimination. In: Franco-Paredes C & Santos-Preciado JI Ed). *Neglected Tropical Diseases – Latin America and the Caribbean*. Springer-Verlag 2015; pp: 175 – 184. (ISBN 978-3-7091-1421-6)
 39. Vermund SH, El-Sadr W, **del Río C**, Wingood GM. Policy and Human Rights Implications of Woman's Poverty and Vulnerability in the USA. In: A. O'Leary & PM Frew: *Poverty in the United States*. Springer Link 2017; pp: 221 – 232. doi: 10.1007/978-3-319-43833-7_13. (ISBN 978-3-319-43831-3)
- f. Books edited and written:
1. **del Río C**, Hernandez G, Uribe P (editores): *Guía para la Atención Domiciliaria de Personas que viven con VIH/SIDA*. CONASIDA 1993. (ISBN 968-811-211-9).
 2. **del Río C** y Uribe P (editores): *Guía para la Atención Psicológica de personas que viven con VIH/SIDA*. CONASIDA 1994. (ISBN 968-811-246-1).
 3. **del Río C**, Hernández Tepichín G, Uribe Zúñiga P (editores): *Guía para la Instalación de Centros de Información sobre VIH/SIDA*. CONASIDA 1994 (ISBN 968-811-342-5).
 4. McCary JL, McCary SP, Alvarez-Gayou JL, del Río C, Suárez JL. *Sexualidad Humana de McCary*. 5a. edición. El Manual Moderno 1996. (ISBN 968-426-707-X).
 5. Ponce de Leon S & **del Río C**. (editores). *Guía para la atención médica del paciente con VIH/SIDA en Consulta Externa y Hospitales*. 2nd Ed. CONASIDA 1996. (ISBN 968-811-291-7) and 3rd Ed. CONASIDA 1997 (ISBN 968-811-617-3).

6. **Institute of Medicine (IOM).** 2004. *Measuring What Matters: Allocation, Planning and Quality Assessment for the Ryan White CARE Act.* Washington DC: The National Academies Press (ISBN 0-309-09115-2)
7. **Institute of Medicine (IOM).** 2008. *Methodological Challenges in Biomedical HIV Prevention Trials.* Washington DC: The National Academies Press. (ISBN 978-309-11430-1)
- g. Book reviews:
 - Guarner J & **del Río C.** Book review, AIDS Pathology. JAMA 1990; 264:1476.
 - **del Río C.** Book Review: Fatal Extraction. Am J Med Sci 1998; 315(5):343-44.
- h. Manuals, videos, computer programs, and other teaching aids:
 - **del Río C** & Lennox J. HIV/AIDS Guideline. In: EBM Solutions (<http://www.ebmsolutions.com/>)
 - **del Río C.** Human Immunodeficiency Virus. In: Clinical Decision Support: Hospital Infection Control, edited by Wenzel, RW and Bearman, G. 2014. Decision Support in Medicine, LLC. Wilmington, DE